{"id":"bendamustine","rwe":[],"_fda":{"id":"5ebe4a1f-c7d6-95a3-8f21-8deebf9bd43a","set_id":"085dd54c-4212-d879-afef-ee52732a48c0","openfda":{"unii":["981Y8SX18M"],"route":["INTRAVENOUS"],"rxcui":["1726097"],"spl_id":["5ebe4a1f-c7d6-95a3-8f21-8deebf9bd43a"],"brand_name":["Bendamustine Hydrochloride"],"spl_set_id":["085dd54c-4212-d879-afef-ee52732a48c0"],"package_ndc":["60505-6228-0"],"product_ndc":["60505-6228"],"generic_name":["BENDAMUSTINE HYDROCHLORIDE"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["BENDAMUSTINE HYDROCHLORIDE"],"manufacturer_name":["Apotex Corp"],"application_number":["NDA215033"],"is_original_packager":[true]},"version":"8","pregnancy":["8.1 Pregnancy Risk Summary In animal reproduction studies, intraperitoneal administration of bendamustine to pregnant mice and rats during organogenesis at doses 0.6 to 1.8 times the maximum recommended human dose (MRHD) resulted in embryo-fetal and/or infant mortality, structural abnormalities, and alterations to growth (see Data). There are no available data on bendamustine hydrochloride use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Bendamustine hydrochloride was intraperitoneally administered once to mice from 210 mg/m 2 (approximately 1.8 times the MRHD) during organogenesis and caused an increase in resorptions, skeletal and visceral malformations (exencephaly, cleft palates, accessory rib, and spinal deformities) and decreased fetal body weights. This dose did not appear to be maternally toxic and lower doses were not evaluated. Repeat intraperitoneal administration of bendamustine hydrochloride in mice on gestation days 7 to 11 resulted in an increase in resorptions from 75 mg/m 2 (approximately 0.6 times the MRHD) and an increase in abnormalities from 112.5 mg/m 2 (approximately 0.9 times the MRHD), similar to those seen after a single intraperitoneal administration. Bendamustine hydrochloride was intraperitoneally administered once to rats from 120 mg/m 2 (approximately the MRHD) on gestation days 4, 7, 9, 11, or 13 and caused embryo and fetal lethality as indicated by increased resorptions and a decrease in live fetuses. A significant increase in external (effect on tail, head, and herniation of external organs [exomphalos]) and internal (hydronephrosis and hydrocephalus) malformations were seen in dosed rats."],"overdosage":["10 OVERDOSAGE The intravenous LD 50 of bendamustine hydrochloride is 240 mg/m 2 in the mouse and rat. Toxicities included sedation, tremor, ataxia, convulsions and respiratory distress. Across all clinical experience, the reported maximum single dose received was 280 mg/m 2 . Three of four patients treated at this dose showed ECG changes considered dose-limiting at 7 and 21 days post-dosing. These changes included QT prolongation (one patient), sinus tachycardia (one patient), ST and T wave deviations (two patients) and left anterior fascicular block (one patient). Cardiac enzymes and ejection fractions remained normal in all patients. No specific antidote for bendamustine hydrochloride overdose is known. Management of overdosage should include general supportive measures, including monitoring of hematologic parameters and ECGs."],"description":["11 DESCRIPTION Bendamustine hydrochloride is an alkylating agent. The chemical name of bendamustine hydrochloride is 1H-benzimidazole-2-butanoic acid, 5-[bis(2-chloroethyl)amino]-1 methyl-, monohydrochloride, monohydrate. Its empirical molecular formula is C 16 H 21 Cl 2 N 3 O 2 · HCl. H 2 O, and the molecular weight is 412.74 g/mol. Bendamustine hydrochloride contains a mechlorethamine group and a benzimidazole heterocyclic ring with a butyric acid substituent, and has the following structural formula: Bendamustine hydrochloride injection for intravenous use is supplied as a sterile, clear, and colorless to yellow solution in a multiple-dose clear glass vial. Each milliliter contains 25 mg of bendamustine hydrochloride, USP, 38 mg (3.8%) absolute ethanol, 5 mg monothioglycerol, NF in polyethylene glycol 400, and 0.08 mg sodium hydroxide is used to adjust the acidity of polyethylene glycol 400 NF. Each mL contains 25 mg Bendamustine hydrochloride, which is equivalent to 22.7 mg Bendamustine free base. Structural-Formula"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING Safe Handling and Disposal Bendamustine hydrochloride injection is a hazardous drug. Follow applicable special handling and disposal procedures 1. Care should be exercised in the handling and preparation of solutions prepared from bendamustine hydrochloride injection. The use of gloves and safety glasses is recommended to avoid exposure in case of breakage of the vial or other accidental spillage. If gloves come in contact with bendamustine hydrochloride injection prior to dilution, remove gloves and follow disposal procedures 1 . If a solution of bendamustine hydrochloride injection contacts the skin, wash the skin immediately and thoroughly with soap and water. If bendamustine hydrochloride injection contacts the mucous membranes, flush thoroughly with water. How Supplied Bendamustine hydrochloride injection is supplied in individual cartons of clear multiple-dose vials containing 100 mg of bendamustine hydrochloride as a clear, and colorless to yellow solution. NDC 60505-6228-0: 100 mg/4 mL (25 mg/mL). Storage Store bendamustine hydrochloride injection in refrigerator, 2ºC to 8ºC (36ºF to 46ºF). Retain in original carton until contents are used to protect from light."],"geriatric_use":["8.5 Geriatric Use No overall differences in safety were observed between patients ≥65 years of age and younger patients. No overall differences in efficacy in patients with non-Hodgkin Lymphoma were observed between geriatric patients and younger patients."],"pediatric_use":["8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. Safety, pharmacokinetics and efficacy were assessed in a single open-label trial (NCT01088984) in patients aged 1 to 19 years with relapsed or refractory acute leukemia, including 27 patients with acute lymphocytic leukemia (ALL) and 16 patients with acute myeloid leukemia (AML). Bendamustine hydrochloride was administered as an intravenous infusion over 60 minutes on Days 1 and 2 of each 21-day cycle. There was no treatment response (CR+ CRp) in any patient. The safety profile in these patients was consistent with that seen in adults, and no new safety signals were identified. The pharmacokinetics of bendamustine in 43 patients, aged 1 to 19 years (median age of 10 years) were within range of values previously observed in adults given the same dose based on body surface area."],"effective_time":"20250916","clinical_studies":["14 CLINICAL STUDIES The efficacy of bendamustine hydrochloride was evaluated in a single arm study of 100 patients with indolent B-cell NHL that had progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Patients were included if they relapsed within 6 months of either the first dose (monotherapy) or last dose (maintenance regimen or combination therapy) of rituximab. All patients received bendamustine hydrochloride intravenously at a dose of 120 mg/m 2 , on Days 1 and 2 of a 21-day treatment cycle. Patients were treated for up to 8 cycles. The median age was 60 years, 65% were male, and 95% had a baseline WHO performance status of 0 or 1. Major tumor subtypes were follicular lymphoma (62%), diffuse small lymphocytic lymphoma (21%), and marginal zone lymphoma (16%). Ninety-nine percent of patients had received previous chemotherapy, 91% of patients had received previous alkylator therapy, and 97% of patients had relapsed within 6 months of either the first dose (monotherapy) or last dose (maintenance regimen or combination therapy) of rituximab. Efficacy was based on the assessments by a blinded independent review committee (IRC) and included overall response rate (complete response + complete response unconfirmed + partial response) and duration of response (DR) as summarized in Table 6. Table 6: Efficacy Data for NHL* Bendamustine Hydrochloride (N=100) Response Rate (%) Overall response rate (CR+CRu+PR) 74 (95% CI) (64.3, 82.3) Complete response (CR) 13 Complete response unconfirmed (CRu) 4 Partial response (PR) 57 Duration of Response (DR) Median, months (95% CI) 9.2 months (7.1, 10.8) CI = confidence interval *IRC assessment was based on modified International Working Group response criteria (IWG-RC). Modifications to IWG-RC specified that a persistently positive bone marrow in patients who met all other criteria for CR would be scored as PR. Bone marrow sample lengths were not required to be ≥20 mm"],"pharmacodynamics":["12.2 Pharmacodynamics Based on the pharmacokinetics/pharmacodynamics analyses of data from adult NHL patients, nausea increased with increasing bendamustine C max . Cardiac Electrophysiology The effect of bendamustine on the QTc interval was evaluated in 53 patients with indolent NHL and mantle cell lymphoma on Day 1 of Cycle 1 after administration of rituximab at 375 mg/m 2 intravenous infusion followed by a 30-minute intravenous infusion of bendamustine at 90 mg/m 2 /day. No mean changes greater than 20 milliseconds were detected up to one hour post infusion. The potential for delayed effects on the QT interval after one hour was not evaluated."],"pharmacokinetics":["12.3 Pharmacokinetics Absorption Following a single IV dose of bendamustine hydrochloride C max typically occurred at the end of infusion. The dose proportionality of bendamustine has not been studied. Distribution The protein binding of bendamustine ranged from 94% to 96% and was concentration independent from 1 to 50 mcg/mL. The blood to plasma concentration ratios in human blood ranged from 0.84 to 0.86 over a concentration range of 10 to 100 mcg/mL. The mean steady-state volume of distribution (V ss ) of bendamustine was approximately 20 to 25 L. Elimination After a single intravenous dose of 120 mg/m 2 of bendamustine over 1 hour, the intermediate half-life (t ½ ) of the parent compound is approximately 40 minutes. The mean terminal elimination t ½ of two active metabolites, γ-hydroxybendamustine (M3) and N-desmethylbendamustine (M4) are approximately 3 hours and 30 minutes, respectively. Bendamustine clearance in humans is approximately 700 mL/min. Metabolism Bendamustine is extensively metabolized via hydrolytic, oxidative, and conjugative pathways. Bendamustine is primarily metabolized via hydrolysis to monohydroxy (HP1) and dihydroxy-bendamustine (HP2) metabolites with low cytotoxic activity in vitro . Two active minor metabolites, M3 and M4, are primarily formed via CYP1A2 in vitro . M3 and M4 concentrations of these metabolites in plasma are 1/10 th and 1/100 th that of the parent compound, respectively. Excretion Following IV infusion of radiolabeled bendamustine hydrochloride in cancer patients, approximately 76% of the dose was recovered. Approximately 50% of the dose was recovered in the urine (3.3% unchanged) and approximately 25% of the dose was recovered in the feces. Less than 1% of the dose was recovered in the urine as M3 and M4, and less than 5% of the dose was recovered in the urine as HP2. Specific Populations No clinically meaningful effects on the pharmacokinetics of bendamustine were observed based on age (31 to 84 years), sex, mild to moderate renal impairment (CLcr ≥ 30 mL/min), or hepatic impairment with total bilirubin 1.5 < ULN and AST or ALT < 2.5 × ULN. The effects of severe renal impairment (CLcr < 30 mL/min), or hepatic impairment with total bilirubin 1.5-3 × ULN and AST or ALT 2.5-10 × ULN or total bilirubin > 3 × ULN on the pharmacokinetics of bendamustine is unknown. Race/Ethnicity Exposures in Japanese subjects (n=6) were 40% higher than that in non-Japanese subjects receiving the same dose. The clinical importance of this difference on the safety and efficacy of bendamustine hydrochloride in Japanese subjects has not been established. Drug Interaction Studies In Vitro Studies Effect of Bendamustine on CYP Substrates Bendamustine did not inhibit CYP1A2, 2C9/10, 2D6, 2E1, or 3A4/5. Bendamustine did not induce metabolism of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, or CYP3A4/5. Effect of Transporters on Bendamustine Hydrochloride Bendamustine is a substrate of P-glycoprotein and breast cancer resistance protein (BCRP)."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant serious adverse reactions are discussed in greater detail in other sections of the prescribing information. Myelosuppression [see Warnings and Precautions ( 5.1 )] Infections [see Warnings and Precautions ( 5.2 )] Progressive Multifocal Leukoencephalopathy [see Warnings and Precautions ( 5.3 )] Anaphylaxis and Infusion Reactions [see Warnings and Precautions ( 5.4 )] Tumor Lysis Syndrome [see Warnings and Precautions ( 5.5 )] Skin Reactions [see Warnings and Precautions ( 5.6 )] Hepatotoxicity [see Warnings and Precautions ( 5.7 )] Other Malignancies [see Warnings and Precautions ( 5.8 )] Extravasation Injury [ see Warnings and Precautions ( 5.9 ) ] Adverse reactions (frequency >5%) during infusion and within 24 hours post-infusion are nausea and fatigue. ( 6.1 ) Most common adverse reactions (≥15%) for NHL are lymphopenia, leukopenia, anemia, neutropenia, thrombocytopenia, nausea, fatigue, vomiting, diarrhea, pyrexia, constipation, anorexia, cough, headache, weight decreased, dyspnea, rash, and stomatitis.( 6.1 ). To report SUSPECTED ADVERSE REACTIONS, contact Apotex Corp. at 1-800-706-5575 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Clinical Trials Experience in NHL The data described below reflect exposure to bendamustine hydrochloride in 176 patients with indolent B-cell NHL treated in two single-arm studies. The population was 31 to 84 years of age, 60% male, and 40% female. The race distribution was 89% White, 7% Black, 3% Hispanic, 1% other, and <1% Asian. These patients received bendamustine hydrochloride at a dose of 120 mg/m 2 intravenously on Days 1 and 2 for up to eight 21-day cycles. The adverse reactions occurring in at least 5% of the NHL patients, regardless of severity, are shown in Table 3. The most common non-hematologic adverse reactions (≥30%) were nausea (75%), fatigue (57%), vomiting (40%), diarrhea (37%) and pyrexia (34%). The most common non-hematologic Grade 3 or 4 adverse reactions (≥5%) were fatigue (11%), febrile neutropenia (6%), and pneumonia, hypokalemia and dehydration, each reported in 5% of patients. Table 3: Non-Hematologic Adverse Reactions Occurring in at Least 5% of NHL Patients Treated with Bendamustine Hydrochloride by System Organ Class and Preferred Term (N=176) Body System Number (%) of patients* Adverse Reaction All Grades Grade 3/4 Total number of patients with at least 1 adverse reaction 176 (100) 94 (53) Cardiac disorders Tachycardia 13 (7) 0 Gastrointestinal disorders Nausea 132 (75) 7 (4) Vomiting 71 (40) 5 (3) Diarrhea 65 (37) 6 (3) Constipation 51 (29) 1 (<1) Stomatitis 27 (15) 1 (<1) Abdominal pain 22 (13) 2 (1) Dyspepsia 20 (11) 0 Gastroesophageal reflux disease 18 (10) 0 Dry mouth 15 (9) 1 (<1) Abdominal pain upper 8 (5) 0 Abdominal distension 8 (5) 0 General disorders and administration site conditions Fatigue 101 (57) 19 (11) Pyrexia 59 (34) 3 (2) Chills 24 (14) 0 Edema peripheral 23 (13) 1 (<1) Asthenia 19 (11) 4 (2) Chest pain 11 (6) 1 (<1) Infusion site pain 11 (6) 0 Pain 10 (6) 0 Catheter site pain 8 (5) 0 Infections and infestations Herpes zoster 18 (10) 5 (3) Upper respiratory tract infection 18 (10) 0 Urinary tract infection 17 (10) 4 (2) Sinusitis 15 (9) 0 Pneumonia 14 (8) 9 (5) Febrile neutropenia 11 (6) 11 (6) Oral candidiasis 11 (6) 2 (1) Nasopharyngitis 11 (6) 0 Investigations Weight decreased 31 (18) 3 (2) Metabolism and nutrition disorders Anorexia 40 (23) 3 (2) Dehydration 24 (14) 8 (5) Decreased appetite 22 (13) 1 (<1) Hypokalemia 15 (9) 9 (5) Musculoskeletal and connective tissue disorders Back pain 25 (14) 5 (3) Arthralgia 11 (6) 0 Pain in extremity 8 (5) 2 (1) Bone pain 8 (5) 0 Nervous system disorders Headache 36 (21) 0 Dizziness 25 (14) 0 Dysgeusia 13 (7) 0 Psychiatric disorder s Insomnia 23 (13) 0 Anxiety 14 (8) 1 (<1) Depression 10 (6) 0 Respiratory, thoracic and mediastinal disorders Cough 38 (22) 1 (<1) Dyspnea 28 (16) 3 (2) Pharyngolaryngeal pain 14 (8) 1 (<1) Wheezing 8 (5) 0 Nasal congestion 8 (5) 0 Skin and subcutaneous tissue disorders Rash 28 (16) 1 (<1) Pruritus 11 (6) 0 Dry skin 9 (5) 0 Night sweats 9 (5) 0 Hyperhidrosis 8 (5) 0 Vascular disorders Hypotension 10 (6) 2 (1) *Patients may have reported more than 1 adverse reaction. NOTE: Patients counted only once in each preferred term category and once in each system organ class category. Hematologic toxicities, based on laboratory values and CTC grade, in NHL patients treated in both single arm studies combined are described in Table 4. Clinically important chemistry laboratory values that were new or worsened from baseline and occurred in >1% of patients at Grade 3 or 4, in NHL patients treated in both single arm studies combined were hyperglycemia (3%), elevated creatinine (2%), hyponatremia (2%), and hypocalcemia (2%). Table 4: Incidence of Hematology Laboratory Abnormalities in Patients Who Received Bendamustine Hydrochloride in the NHL Studies Hematology Variable Percent of Patients All Grades Grade 3/4 Lymphocytes Decreased 99 94 Leukocytes Decreased 94 56 Hemoglobin Decreased 88 11 Neutrophils Decreased 86 60 Platelets Decreased 86 25 In both studies, serious adverse reactions, regardless of causality, were reported in 37% of patients receiving bendamustine hydrochloride. The most common serious adverse reactions occurring in ≥5% of patients were febrile neutropenia and pneumonia. Other important serious adverse reactions reported in clinical trials and/or post-marketing experience were acute renal failure, cardiac failure, hypersensitivity, skin reactions, pulmonary fibrosis, and myelodysplastic syndrome. Serious drug-related adverse reactions reported in clinical trials included myelosuppression, infection, pneumonia, tumor lysis syndrome and infusion reactions. Adverse reactions occurring less frequently but possibly related to bendamustine hydrochloride treatment were hemolysis, dysgeusia/taste disorder, atypical pneumonia, sepsis, herpes zoster, erythema, dermatitis, and skin necrosis. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of bendamustine hydrochloride. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic systems disorders : Pancytopenia Cardiovascular disorders : Atrial fibrillation, congestive heart failure (some fatal), myocardial infarction (some fatal), palpitation General disorders and administration site conditions : Injection site reactions (including phlebitis, pruritus, irritation, pain, swelling), infusion site reactions (including phlebitis, pruritus, irritation, pain, swelling) Immune system disorders : Anaphylaxis Infections and infestations : Pneumocystis jirovecii pneumonia, progressive multifocal leukoencephalopathy (PML) Renal and urinary disorders: Nephrogenic diabetes insipidus (NDI) Respiratory, thoracic and mediastinal disorders : Pneumonitis Skin and subcutaneous tissue disorders: Drug reaction with eosinophilia and systemic symptoms (DRESS), non-melanoma skin cancer (NMSC), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)."],"contraindications":["4 CONTRAINDICATIONS Bendamustine hydrochloride injection is contraindicated in patients with a known hypersensitivity (e.g., anaphylactic and anaphylactoid reactions) to bendamustine, polyethylene glycol 400, absolute ethanol, sodium hydroxide and monothioglycerol. [see Warnings and Precautions ( 5.4 )] Bendamustine hydrochloride injection is contraindicated in patients with a history of a hypersensitivity reaction to bendamustine, polyethylene glycol 400, absolute ethanol, sodium hydroxide and monothioglycerol. Reactions to bendamustine hydrochloride have included anaphylaxis and anaphylactoid reactions. ( 4 , 5.4 )"],"drug_interactions":["7 DRUG INTERACTIONS Consider alternative therapies that are not CYP1A2 inducers or inhibitors during treatment with bendamustine hydrochloride injection. ( 7.1 ) 7.1 Effect of Other Drugs on Bendamustine Hydrochloride Injection CYP1A2 Inhibitors The coadministration of bendamustine hydrochloride injection with CYP1A2 inhibitors may increase bendamustine plasma concentrations and may result in increased incidence of adverse reactions with bendamustine hydrochloride injection [see Clinical Pharmacology ( 12.3 )]. Consider alternative therapies that are not CYP1A2 inhibitors during treatment with bendamustine hydrochloride injection. CYP1A2 Inducers The coadministration of bendamustine hydrochloride injection with CYP1A2 inducers may decrease bendamustine plasma concentrations and may result in decreased efficacy of bendamustine hydrochloride injection [see Clinical Pharmacology ( 12.3 )]. Consider alternative therapies that are not CYP1A2 inducers during treatment with bendamustine hydrochloride injection."],"mechanism_of_action":["12.1 Mechanism of Action Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown."],"recent_major_changes":["RECENT MAJOR CHANGES SECTION Indications and Usage, Chronic Lymphocytic Leukemia (CLL) indication removed ( 1.1 ) 04/2024 Dosage and Administration, Dosing Instructions for CLL removed ( 2.1 ) 04/2024"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown. 12.2 Pharmacodynamics Based on the pharmacokinetics/pharmacodynamics analyses of data from adult NHL patients, nausea increased with increasing bendamustine C max . Cardiac Electrophysiology The effect of bendamustine on the QTc interval was evaluated in 53 patients with indolent NHL and mantle cell lymphoma on Day 1 of Cycle 1 after administration of rituximab at 375 mg/m 2 intravenous infusion followed by a 30-minute intravenous infusion of bendamustine at 90 mg/m 2 /day. No mean changes greater than 20 milliseconds were detected up to one hour post infusion. The potential for delayed effects on the QT interval after one hour was not evaluated. 12.3 Pharmacokinetics Absorption Following a single IV dose of bendamustine hydrochloride C max typically occurred at the end of infusion. The dose proportionality of bendamustine has not been studied. Distribution The protein binding of bendamustine ranged from 94% to 96% and was concentration independent from 1 to 50 mcg/mL. The blood to plasma concentration ratios in human blood ranged from 0.84 to 0.86 over a concentration range of 10 to 100 mcg/mL. The mean steady-state volume of distribution (V ss ) of bendamustine was approximately 20 to 25 L. Elimination After a single intravenous dose of 120 mg/m 2 of bendamustine over 1 hour, the intermediate half-life (t ½ ) of the parent compound is approximately 40 minutes. The mean terminal elimination t ½ of two active metabolites, γ-hydroxybendamustine (M3) and N-desmethylbendamustine (M4) are approximately 3 hours and 30 minutes, respectively. Bendamustine clearance in humans is approximately 700 mL/min. Metabolism Bendamustine is extensively metabolized via hydrolytic, oxidative, and conjugative pathways. Bendamustine is primarily metabolized via hydrolysis to monohydroxy (HP1) and dihydroxy-bendamustine (HP2) metabolites with low cytotoxic activity in vitro . Two active minor metabolites, M3 and M4, are primarily formed via CYP1A2 in vitro . M3 and M4 concentrations of these metabolites in plasma are 1/10 th and 1/100 th that of the parent compound, respectively. Excretion Following IV infusion of radiolabeled bendamustine hydrochloride in cancer patients, approximately 76% of the dose was recovered. Approximately 50% of the dose was recovered in the urine (3.3% unchanged) and approximately 25% of the dose was recovered in the feces. Less than 1% of the dose was recovered in the urine as M3 and M4, and less than 5% of the dose was recovered in the urine as HP2. Specific Populations No clinically meaningful effects on the pharmacokinetics of bendamustine were observed based on age (31 to 84 years), sex, mild to moderate renal impairment (CLcr ≥ 30 mL/min), or hepatic impairment with total bilirubin 1.5 < ULN and AST or ALT < 2.5 × ULN. The effects of severe renal impairment (CLcr < 30 mL/min), or hepatic impairment with total bilirubin 1.5-3 × ULN and AST or ALT 2.5-10 × ULN or total bilirubin > 3 × ULN on the pharmacokinetics of bendamustine is unknown. Race/Ethnicity Exposures in Japanese subjects (n=6) were 40% higher than that in non-Japanese subjects receiving the same dose. The clinical importance of this difference on the safety and efficacy of bendamustine hydrochloride in Japanese subjects has not been established. Drug Interaction Studies In Vitro Studies Effect of Bendamustine on CYP Substrates Bendamustine did not inhibit CYP1A2, 2C9/10, 2D6, 2E1, or 3A4/5. Bendamustine did not induce metabolism of CYP1A2, CYP2A6, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2E1, or CYP3A4/5. Effect of Transporters on Bendamustine Hydrochloride Bendamustine is a substrate of P-glycoprotein and breast cancer resistance protein (BCRP)."],"indications_and_usage":["1 INDICATIONS AND USAGE Non-Hodgkin Lymphoma (NHL) Bendamustine hydrochloride injection is indicated for the treatment of adult patients with indolent B-cell non-Hodgkin lymphoma that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine hydrochloride injection is an alkylating drug indicated for treatment of adult patients with: • Indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Myelosuppression: Delay or reduce dose and restart treatment based on ANC and platelet count recovery. ( 5.1 ) Infections: Monitor for fever and other signs of infection or reactivation of infections and treat promptly. ( 5.2 ) Progressive multifocal leukoencephalopathy (PML): Monitor for new or worsening neurological, cognitive or behavioral signs or symptoms suggestive of PML. ( 5.3 ) Anaphylaxis and Infusion Reactions: Severe anaphylactic reactions have occurred. Monitor clinically and discontinue drug for severe reactions. Pre-medicate in subsequent cycles for milder reactions. ( 5.4 ) Tumor Lysis Syndrome: May lead to acute renal failure and death; anticipate and use supportive measures in patients at high risk. ( 5.5 ) Skin Reactions: Discontinue for severe skin reactions. Cases of SJS, DRESS and TEN, some fatal, have been reported. ( 5.6 ) Hepatotoxicity: Monitor liver chemistry tests prior to and during treatment. ( 5.7 ) Other Malignancies: Pre-malignant and malignant diseases have been reported. ( 5.8 ) Extravasation Injury: Take precautions to avoid extravasation, including monitoring intravenous infusion site during and after administration. ( 5.9 ) Embryo-Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with female partners of reproductive potential of the potential risk to a fetus and to use an effective method of contraception. ( 5.10 , 8.1 , 8.3 ) 5.1 Myelosuppression Bendamustine hydrochloride caused severe myelosuppression (Grade 3 to 4) in 98% of patients in the two NHL studies [see Adverse Reactions ( 6.1 )] . Three patients (2%) died from myelosuppression-related adverse reactions; one each from neutropenic sepsis, diffuse alveolar hemorrhage with Grade 3 thrombocytopenia, and pneumonia from an opportunistic infection (CMV). Bendamustine hydrochloride injection causes myelosuppression. Monitor complete blood counts, including leukocytes, platelets, hemoglobin (Hgb), and neutrophils frequently. In the clinical trials, blood counts were monitored every week initially. Hematologic nadirs were observed predominantly in the third week of therapy. Myelosuppression may require dose delays and/or subsequent dose reductions if recovery to the recommended values has not occurred by the first day of the next scheduled cycle. Prior to the initiation of the next cycle of therapy, the ANC should be ≥ 1 x 10 9 /L and the platelet count should be ≥ 75 x 10 9 /L. [see Dosage and Administration ( 2.2 )]. 5.2 Infections Infection, including pneumonia, sepsis, septic shock, hepatitis and death has occurred in adult and pediatric patients in clinical trials and in postmarketing reports for bendamustine hydrochloride [see Adverse Reactions ( 6.1 , 6.2)] . Patients with myelosuppression following treatment with bendamustine hydrochloride are more susceptible to infections. Advise patients with myelosuppression following bendamustine hydrochloride injection treatment to contact a physician immediately if they have symptoms or signs of infection. Patients treated with bendamustine hydrochloride injection are at risk for reactivation of infections including (but not limited to) hepatitis B, cytomegalovirus, Mycobacterium tuberculosis, and herpes zoster. Patients should undergo appropriate measures (including clinical and laboratory monitoring, prophylaxis, and treatment) for infection and infection reactivation prior to administration. 5.3 Progressive Multifocal Leukoencephalopathy (PML) Progressive multifocal leukoencephalopathy (PML), including fatal cases, have occurred following treatment with bendamustine hydrochloride, primarily in combination with rituximab or obinutuzumab [see Adverse Reactions ( 6.2 )] . Consider PML in the differential diagnosis in patients with new or worsening neurological, cognitive or behavioral signs or symptoms. If PML is suspected, withhold bendamustine hydrochloride injection treatment and perform appropriate diagnostic evaluations. Consider discontinuation or reduction of any concomitant chemotherapy or immunosuppressive therapy in patients who develop PML. 5.4 Anaphylaxis and Infusion Reactions Infusion reactions to bendamustine hydrochloride have occurred commonly in clinical trials [see Adverse Reactions ( 6.1 )] . Symptoms include fever, chills, pruritus and rash. In rare instances severe anaphylactic and anaphylactoid reactions have occurred, particularly in the second and subsequent cycles of therapy. Monitor clinically and discontinue drug for severe reactions. Ask patients about symptoms suggestive of infusion reactions after their first cycle of therapy. Patients who experience Grade 3 or worse allergic-type reactions should not be rechallenged. Consider measures to prevent severe reactions, including antihistamines, antipyretics and corticosteroids in subsequent cycles in patients who have experienced Grade 1 or 2 infusion reactions. Discontinue bendamustine hydrochloride injection for patients with Grade 4 infusion reactions. Consider discontinuation for Grade 3 infusion reactions as clinically appropriate considering individual benefits, risks, and supportive care. 5.5 Tumor Lysis Syndrome Tumor lysis syndrome associated with bendamustine hydrochloride has occurred in patients in clinical trials and in post-marketing reports [see Adverse Reactions ( 6.1 )] . The onset tends to be within the first treatment cycle of bendamustine hydrochloride and, without intervention, may lead to acute renal failure and death. Preventive measures include vigorous hydration and close monitoring of blood chemistry, particularly potassium and uric acid levels. Allopurinol has also been used during the beginning of bendamustine hydrochloride therapy. However, there may be an increased risk of severe skin toxicity when bendamustine hydrochloride and allopurinol are administered concomitantly [see Warnings and Precautions (5.6) ]. 5.6 Skin Reactions Fatal and serious skin reactions have been reported with bendamustine hydrochloride treatment in clinical trials and postmarketing safety reports, including toxic skin reactions [Stevens-Johnson Syndrome (SJS), toxic epidermal necrolysis (TEN), and drug reaction with eosinophilia and systemic symptoms (DRESS), bullous exanthema, and rash [see Adverse Reactions ( 6.1 and 6.2 )]. Events occurred when bendamustine hydrochloride was given as a single agent and in combination with other anticancer agents or allopurinol. Where skin reactions occur, they may be progressive and increase in severity with further treatment. Monitor patients with skin reactions closely. If skin reactions are severe or progressive, withhold or discontinue bendamustine hydrochloride injection. 5.7 Hepatotoxicity Fatal and serious cases of liver injury have been reported with bendamustine hydrochloride injection [see Adverse Reactions ( 6.1 )]. Combination therapy, progressive disease or reactivation of hepatitis B were confounding factors in some patients [see Warnings and Precautions ( 5.2 ) ]. Most cases were reported within the first three months of starting therapy. Monitor liver chemistry tests prior to and during bendamustine hydrochloride injection therapy. 5.8 Other Malignancies There are reports of pre-malignant and malignant diseases that have developed in patients who have been treated with bendamustine hydrochloride, including myelodysplastic syndrome, myeloproliferative disorders, acute myeloid leukemia, bronchial carcinoma, and non-melanoma skin cancer, including basal cell carcinoma and squamous cell carcinoma [see Adverse Reactions ( 6.2 )] . Monitor patients for the development of secondary malignancies. Perform dermatologic evaluations during and after treatment with bendamustine hydrochloride injection. 5.9 Extravasation Injury Bendamustine hydrochloride extravasations have been reported in postmarketing resulting in hospitalizations from erythema, marked swelling, and pain [see Adverse Reactions ( 6.2 )] . Assure good venous access prior to starting bendamustine hydrochloride injection infusion and monitor the intravenous infusion site for redness, swelling, pain, infection, and necrosis during and after administration of bendamustine hydrochloride injection. 5.10 Embryo-Fetal Toxicity Based on findings from animal reproduction studies and the drug’s mechanism of action, bendamustine hydrochloride injection can cause fetal harm when administered to a pregnant woman. Single intraperitoneal doses of bendamustine (that approximated the maximum recommended human dose based on body surface area) to pregnant mice and rats during organogenesis caused adverse developmental outcomes, including an increase in resorptions, skeletal and visceral malformations, and decreased fetal body weights. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use an effective method of contraception during treatment with bendamustine hydrochloride injection and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with bendamustine hydrochloride injection and for 3 months after the last dose [see Use in Specific Populations ( 8.1 , 8.3 ) and Clinical Pharmacology ( 12.1 )] ."],"clinical_studies_table":["<table frame=\"border\" rules=\"all\"><thead><tr><td> </td><td align=\"center\"><content styleCode=\"bold\">Bendamustine Hydrochloride </content><content styleCode=\"bold\"> (N=100)</content></td></tr></thead><tbody align=\"center\"><tr><td align=\"left\"><content styleCode=\"bold\">Response Rate (%)</content></td><td> </td></tr><tr><td align=\"left\"> Overall response rate (CR+CRu+PR) </td><td> 74 </td></tr><tr><td align=\"left\"> (95% CI) </td><td> (64.3, 82.3) </td></tr><tr><td align=\"left\"> Complete response (CR) </td><td> 13 </td></tr><tr><td align=\"left\"> Complete response unconfirmed (CRu) </td><td> 4 </td></tr><tr><td align=\"left\"> Partial response (PR) </td><td> 57 </td></tr><tr><td align=\"left\"><content styleCode=\"bold\">Duration of Response (DR)</content></td><td> </td></tr><tr><td align=\"left\"> Median, months (95% CI) </td><td> 9.2 months (7.1, 10.8) </td></tr></tbody></table>"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Bendamustine was carcinogenic in mice. After intraperitoneal injections at 37.5 mg/m 2 /day (the lowest dose tested, approximately 0.3 times the maximum recommended human dose [MRHD]) and 75 mg/m 2 /day (approximately 0.6 times the MRHD) for 4 days, peritoneal sarcomas in female AB/jena mice were produced. Oral administration at 187.5 mg/m 2 /day (the only dose tested, approximately 1.6 times the MRHD) for 4 days induced mammary carcinomas and pulmonary adenomas. Bendamustine is a mutagen and clastogen. In a reverse bacterial mutation assay (Ames assay), bendamustine was shown to increase revertant frequency in the absence and presence of metabolic activation. Bendamustine was clastogenic in human lymphocytes in vitro, and in rat bone marrow cells in vivo (increase in micronucleated polychromatic erythrocytes) from 37.5 mg/m 2 (the lowest dose tested, approximately 0.3 times the MRHD). Bendamustine induced morphologic abnormalities in spermatozoa in mice. Following tail vein injection of bendamustine at 120 mg/m 2 or a saline control on days 1 and 2 for a total of 3 weeks, the number of spermatozoa with morphologic abnormalities was 16% higher in the bendamustine-treated group as compared to the saline control group."],"adverse_reactions_table":["<table frame=\"border\" rules=\"all\"><thead><tr><td><content styleCode=\"bold\">Body System </content><content styleCode=\"bold\"/></td><td align=\"center\" colspan=\"2\"><content styleCode=\"bold\">Number (%) of patients*</content></td></tr><tr><td><content styleCode=\"bold\">Adverse Reaction</content></td><td align=\"center\"><content styleCode=\"bold\">All Grades</content></td><td align=\"center\"><content styleCode=\"bold\">Grade 3/4</content></td></tr></thead><tbody align=\"center\"><tr><td><content styleCode=\"bold\">Total number of patients with at </content><content styleCode=\"bold\">least 1 adverse reaction</content></td><td align=\"center\"> 176 (100) </td><td> 94 (53) </td></tr><tr><td align=\"left\" colspan=\"3\"><content styleCode=\"bold\">Cardiac disorders</content></td></tr><tr><td align=\"left\"> Tachycardia </td><td align=\"center\"> 13 (7) </td><td> 0 </td></tr><tr><td align=\"left\" colspan=\"3\"><content styleCode=\"bold\">Gastrointestinal disorders</content></td></tr><tr><td align=\"left\"> Nausea </td><td align=\"center\"> 132 (75) </td><td> 7 (4) </td></tr><tr><td align=\"left\"> Vomiting </td><td align=\"center\"> 71 (40) </td><td> 5 (3) </td></tr><tr><td align=\"left\"> Diarrhea </td><td> 65 (37) </td><td> 6 (3) </td></tr><tr><td align=\"left\"> Constipation </td><td> 51 (29) </td><td> 1 (&lt;1) </td></tr><tr><td align=\"left\"> Stomatitis </td><td> 27 (15) </td><td> 1 (&lt;1) </td></tr><tr><td align=\"left\"> Abdominal pain </td><td> 22 (13) </td><td> 2 (1) </td></tr><tr><td align=\"left\"> Dyspepsia </td><td> 20 (11) </td><td> 0 </td></tr><tr><td align=\"left\"> Gastroesophageal reflux disease </td><td> 18 (10) </td><td> 0 </td></tr><tr><td align=\"left\"> Dry mouth </td><td> 15 (9) </td><td> 1 (&lt;1) </td></tr><tr><td align=\"left\"> Abdominal pain upper </td><td> 8 (5) </td><td> 0 </td></tr><tr><td align=\"left\"> Abdominal distension </td><td> 8 (5) </td><td> 0 </td></tr><tr><td align=\"left\" colspan=\"3\"><content styleCode=\"bold\">General disorders and administration site conditions</content></td></tr><tr><td align=\"left\"> Fatigue </td><td> 101 (57) </td><td> 19 (11) </td></tr><tr><td align=\"left\"> Pyrexia </td><td> 59 (34) </td><td> 3 (2) </td></tr><tr><td align=\"left\"> Chills </td><td> 24 (14) </td><td> 0 </td></tr><tr><td align=\"left\"> Edema peripheral </td><td> 23 (13) </td><td> 1 (&lt;1) </td></tr><tr><td align=\"left\"> Asthenia </td><td> 19 (11) </td><td> 4 (2) </td></tr><tr><td align=\"left\"> Chest pain </td><td> 11 (6) </td><td> 1 (&lt;1) </td></tr><tr><td align=\"left\"> Infusion site pain </td><td> 11 (6) </td><td> 0 </td></tr><tr><td align=\"left\"> Pain </td><td> 10 (6) </td><td> 0 </td></tr><tr><td align=\"left\"> Catheter site pain </td><td> 8 (5) </td><td> 0 </td></tr><tr><td align=\"left\" colspan=\"3\"><content styleCode=\"bold\">Infections and infestations</content></td></tr><tr><td align=\"left\"> Herpes zoster </td><td> 18 (10) </td><td> 5 (3) </td></tr><tr><td align=\"left\"> Upper respiratory tract infection </td><td> 18 (10) </td><td> 0 </td></tr><tr><td align=\"left\"> Urinary tract infection </td><td> 17 (10) </td><td> 4 (2) </td></tr><tr><td align=\"left\"> Sinusitis </td><td> 15 (9) </td><td> 0 </td></tr><tr><td align=\"left\"> Pneumonia </td><td> 14 (8) </td><td> 9 (5) </td></tr><tr><td align=\"left\"> Febrile neutropenia </td><td> 11 (6) </td><td> 11 (6) </td></tr><tr><td align=\"left\"> Oral candidiasis </td><td> 11 (6) </td><td> 2 (1) </td></tr><tr><td align=\"left\"> Nasopharyngitis </td><td> 11 (6) </td><td> 0 </td></tr><tr><td align=\"left\" colspan=\"3\"><content styleCode=\"bold\">Investigations</content></td></tr><tr><td align=\"left\"> Weight decreased </td><td> 31 (18) </td><td> 3 (2) </td></tr><tr><td align=\"left\" colspan=\"3\"><content styleCode=\"bold\">Metabolism and nutrition disorders</content></td></tr><tr><td align=\"left\"> Anorexia </td><td> 40 (23) </td><td> 3 (2) </td></tr><tr><td align=\"left\"> Dehydration </td><td> 24 (14) </td><td> 8 (5) </td></tr><tr><td align=\"left\"> Decreased appetite </td><td> 22 (13) </td><td> 1 (&lt;1) </td></tr><tr><td align=\"left\"> Hypokalemia </td><td> 15 (9) </td><td> 9 (5) </td></tr><tr><td align=\"left\" colspan=\"3\"><content styleCode=\"bold\">Musculoskeletal and connective tissue disorders</content></td></tr><tr><td align=\"left\"> Back pain </td><td> 25 (14) </td><td> 5 (3) </td></tr><tr><td align=\"left\"> Arthralgia </td><td> 11 (6) </td><td> 0 </td></tr><tr><td align=\"left\"> Pain in extremity </td><td> 8 (5) </td><td> 2 (1) </td></tr><tr><td align=\"left\"> Bone pain </td><td> 8 (5) </td><td> 0 </td></tr><tr><td align=\"left\" colspan=\"3\"><content styleCode=\"bold\">Nervous system disorders</content></td></tr><tr><td align=\"left\"> Headache </td><td> 36 (21) </td><td> 0 </td></tr><tr><td align=\"left\"> Dizziness </td><td> 25 (14) </td><td> 0 </td></tr><tr><td align=\"left\"> Dysgeusia </td><td> 13 (7) </td><td> 0 </td></tr><tr><td align=\"left\" colspan=\"3\"><content styleCode=\"bold\">Psychiatric disorder</content><content styleCode=\"bold\">s</content></td></tr><tr><td align=\"left\"> Insomnia </td><td> 23 (13) </td><td> 0 </td></tr><tr><td align=\"left\"> Anxiety </td><td> 14 (8) </td><td> 1 (&lt;1) </td></tr><tr><td align=\"left\"> Depression </td><td> 10 (6) </td><td> 0 </td></tr><tr><td align=\"left\" colspan=\"3\"><content styleCode=\"bold\">Respiratory, thoracic and mediastinal disorders</content></td></tr><tr><td align=\"left\"> Cough </td><td> 38 (22) </td><td> 1 (&lt;1) </td></tr><tr><td align=\"left\"> Dyspnea </td><td> 28 (16) </td><td> 3 (2) </td></tr><tr><td align=\"left\"> Pharyngolaryngeal pain </td><td> 14 (8) </td><td> 1 (&lt;1) </td></tr><tr><td align=\"left\"> Wheezing </td><td> 8 (5) </td><td> 0 </td></tr><tr><td align=\"left\"> Nasal congestion </td><td> 8 (5) </td><td> 0 </td></tr><tr><td align=\"left\" colspan=\"3\"><content styleCode=\"bold\">Skin and subcutaneous tissue disorders</content></td></tr><tr><td align=\"left\"> Rash </td><td> 28 (16) </td><td> 1 (&lt;1) </td></tr><tr><td align=\"left\"> Pruritus </td><td> 11 (6) </td><td> 0 </td></tr><tr><td align=\"left\"> Dry skin </td><td> 9 (5) </td><td> 0 </td></tr><tr><td align=\"left\"> Night sweats </td><td> 9 (5) </td><td> 0 </td></tr><tr><td align=\"left\"> Hyperhidrosis </td><td> 8 (5) </td><td> 0 </td></tr><tr><td align=\"left\" colspan=\"3\"><content styleCode=\"bold\">Vascular disorders</content></td></tr><tr><td align=\"left\"> Hypotension </td><td> 10 (6) </td><td> 2 (1) </td></tr></tbody></table>","<table frame=\"border\" rules=\"all\"><thead><tr><td rowspan=\"2\"><content styleCode=\"bold\">Hematology Variable</content></td><td align=\"center\" colspan=\"2\"><content styleCode=\"bold\">Percent of Patients</content></td></tr><tr><td><content styleCode=\"bold\">All Grades</content></td><td><content styleCode=\"bold\">Grade 3/4</content></td></tr></thead><tbody align=\"center\"><tr><td align=\"left\"> Lymphocytes Decreased </td><td> 99 </td><td> 94 </td></tr><tr><td align=\"left\"> Leukocytes Decreased </td><td> 94 </td><td> 56 </td></tr><tr><td align=\"left\"> Hemoglobin Decreased </td><td> 88 </td><td> 11 </td></tr><tr><td align=\"left\"> Neutrophils Decreased </td><td> 86 </td><td> 60 </td></tr><tr><td align=\"left\"> Platelets Decreased </td><td> 86 </td><td> 25 </td></tr></tbody></table>"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Myelosuppression Inform patients of the likelihood that bendamustine hydrochloride injection will cause a decrease in white blood cells, platelets, and red blood cells, and the need for frequent monitoring of blood counts. Advise patients to report shortness of breath, significant fatigue, bleeding, fever, or other signs of infection [see Warnings and Precautions ( 5.1 )]. Progressive Multifocal Leukoencephalopathy (PML) Inform patients to immediately contact their healthcare provider if they experience confusion, memory loss, trouble thinking, difficulty talking or walking, vision loss or other neurological or cognitive symptoms [see Warnings and Precautions ( 5.3 )] . Anaphylaxis and Infusion Reactions Inform patients of the possibility of serious or mild allergic reactions and to immediately report rash, facial swelling, or difficulty breathing during or soon after infusion. [see Warnings and Precautions ( 5.4 )] Skin Reactions Advise patients that a rash or itching may occur during treatment with bendamustine hydrochloride injection. Advise patients to immediately report severe or worsening rash or itching. [see Warnings and Precautions ( 5.6 )] Hepatotoxicity Inform patients of the possibility of developing liver function abnormalities and serious hepatic toxicity. Advise patients to immediately contact their health care provider if signs of liver failure occur, including jaundice, anorexia, bleeding or bruising [see Warnings and Precautions ( 5.7 )] . Fatigue Advise patients that bendamustine hydrochloride injection may cause tiredness and to avoid driving any vehicle or operating any dangerous tools or machinery if they experience this side effect [see Adverse Reactions ( 6.1 )] . Nausea and Vomiting Advise patients that bendamustine hydrochloride injection may cause nausea and/or vomiting. Patients should report nausea and vomiting so that symptomatic treatment may be provided [see Adverse Reactions ( 6.1 ) ] . Diarrhea Advise patients that bendamustine hydrochloride injection may cause diarrhea. Patients should report diarrhea to the physician so that symptomatic treatment may be provided [see Adverse Reactions ( 6.1 )]. Non-melanoma Skin Cancer (NMSC) Advise patients to undergo regular skin cancer screenings, and to report any suspicious skin changes to their healthcare provider [see Warnings and Precautions ( 5.8 )]. Embryo-Fetal Toxicity Advise pregnant women and females of reproductive potential of the potential risk to a fetus. Advise females to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions ( 5.10 ), Use in Specific Populations ( 8.1 , 8.3 ), and Nonclinical Toxicology ( 13.1 )]. Advise female patients of reproductive potential to use effective contraception during treatment with bendamustine hydrochloride injection and for 6 months after the last dose [see Use in Specific Populations ( 8.1 , 8.3 )]. Advise males with female partners of reproductive potential to use effective contraception during treatment with bendamustine hydrochloride injection and for 3 months after the last dose [see Use in Specific Populations ( 8.3 ), and Nonclinical Toxicology ( 13.1 )]. Lactation Advise females not to breastfeed during treatment with bendamustine hydrochloride injection and for 1 week after the last dose [see Use in Specific Populations ( 8.2 )]. Infertility Advise males of reproductive potential that bendamustine hydrochloride injection may impair fertility [see Use in Specific Populations ( 8.3 )]. Manufactured by: Manufactured for: MSN Laboratories Private Limited, India Apotex Corp. ML No. 5/MN/TS/2014/F/G Weston, Florida USA 33326 Rev 3"],"spl_unclassified_section":["15 REFERENCES 1. OSHA Hazardous Drugs. OSHA. [ http://www.osha.gov/SLTC/hazardousdrugs/index.html ]"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION For NHL : • 120 mg/m 2 infused intravenously over 60 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles ( 2.1 ) 2.1 Dosing Instructions for NHL Recommended Dosage: The recommended dosage is 120 mg/m 2 administered intravenously over 60 minutes on Days 1 and 2 of a 21-day cycle, up to 8 cycles. Dose Delays, Dosage Modifications and Reinitiation of Therapy for NHL: Delay bendamustine hydrochloride injection administration in the event of a Grade 4 hematologic toxicity or clinically significant greater or equal to Grade 2 non-hematologic toxicity. Once non-hematologic toxicity has recovered to ≤ Grade 1 and/or the blood counts have improved [Absolute Neutrophil Count (ANC) ≥ 1 x 10 9 /L, platelets ≥ 75 x 10 9 /L], reinitiate bendamustine hydrochloride injection at the discretion of the treating physician. In addition, consider dose reduction. [ see Warnings and Precautions ( 5.1 )] Dosage modifications for hematologic toxicity: for Grade 4 toxicity, reduce the dose to 90 mg/m 2 on Days 1 and 2 of each cycle; if Grade 4 toxicity recurs, reduce the dose to 60 mg/m 2 on Days 1 and 2 of each cycle. Dosage modifications for non-hematologic toxicity: for Grade 3 or greater toxicity, reduce the dose to 90 mg/m 2 on Days 1 and 2 of each cycle; if Grade 3 or greater toxicity recurs, reduce the dose to 60 mg/m 2 on Days 1 and 2 of each cycle. 2.2 Preparation for Intravenous Administration Bendamustine hydrochloride injection is a hazardous drug. Follow applicable special handling and disposal procedures. 1 Bendamustine hydrochloride injection is in a multiple-dose vial. Bendamustine hydrochloride injection is a clear and colorless to yellow solution. Store bendamustine hydrochloride injection at recommended refrigerated storage conditions (2°C to 8°C or 36°F to 46°F). When refrigerated the contents may freeze. Allow the vial to reach room temperature (15°C to 30°C or 59°F to 86°F) prior to use. Observe the contents of the vial for any visible solid or particulate matter and discoloration. Do not use the product if solid or particulate matter is observed after reaching room temperature. Intravenous Infusion Aseptically withdraw the volume needed for the required dose from the 25 mg/mL solution as per Table A below and immediately transfer to a 500 mL infusion bag of one of the following diluents: - 0.9% Sodium Chloride Injection, USP; or - 2.5% Dextrose/0.45% Sodium Chloride Injection, USP. The resulting final concentration of bendamustine hydrochloride injection in the infusion bag should be within 0.05 mg/mL to 0.7 mg/mL. After transferring, thoroughly mix the contents of the infusion bag. The admixture should be a clear and colorless to slightly yellow solution. Use either 0.9% Sodium Chloride Injection, USP, or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP, for dilution, as outlined above. No other diluents have been shown to be compatible. Table A: Volume (mL) of Bendamustine Hydrochloride Injection required for dilution into 500 mL of 0.9% Sodium Chloride Injection, USP, or 0.45% Sodium Chloride/2.5% Dextrose Injection, USP for a given dose (mg/m 2 ) and Body Surface Area (m 2 ) Body Surface Area (m 2 ) Volume of Bendamustine Hydrochloride Injection to withdraw (mL) 120 mg/m 2 90 mg/m 2 60 mg/m 2 1 4.8 3.6 2.4 1.1 5.3 4 2.6 1.2 5.8 4.3 2.9 1.3 6.2 4.7 3.1 1.4 6.7 5 3.4 1.5 7.2 5.4 3.6 1.6 7.7 5.8 3.8 1.7 8.2 6.1 4.1 1.8 8.6 6.5 4.3 1.9 9.1 6.8 4.6 2 9.6 7.2 4.8 2.1 10.1 7.6 5 2.2 10.6 7.9 5.3 2.3 11 8.3 5.5 2.4 11.5 8.6 5.8 2.5 12 9 6 2.6 12.5 9.4 6.2 2.7 13 9.7 6.5 2.8 13.4 10.1 6.7 2.9 13.9 10.4 7 3 14.4 10.8 7.2 Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. Any unused solution should be discarded according to institutional procedures for antineoplastics. 2.3 Admixture Stability Bendamustine hydrochloride injection contains no antimicrobial preservative. The admixture should be prepared as close as possible to the time of patient administration. If diluted with 0.9% Sodium Chloride Injection, USP, or 2.5% Dextrose/0.45% Sodium Chloride Injection, USP, the final admixture is stable for 24 hours when stored refrigerated (2°C to 8°C or 36°F to 46°F) or for 3 hours when stored at room temperature (15°C to 30°C or 59°F to 86°F) and room light. Administration of diluted bendamustine hydrochloride injection must be completed within this period of time. Bendamustine hydrochloride injection is supplied in a multiple-dose vial. Retain the partially used vial in original package to protect from light and store refrigerated (2°C to 8°C or 36°F to 46°F) if additional dose withdrawal from the same vial is intended. 2.4 Stability of Partially Used Vials (Needle Punched Vials) Bendamustine hydrochloride injection is supplied as a multiple-dose vial. Although it does not contain any antimicrobial preservative, bendamustine hydrochloride injection is bacteriostatic. The partially used vials are stable for up to 28 days when stored in its original carton under refrigeration (2°C to 8°C or 36°F to 46°F). Each vial is not recommended for more than a total of six (6) dose withdrawals. After first use, store the partially used vial in original carton at 2°C to 8°C (36°F to 46°F), and then discard after 28 days."],"spl_product_data_elements":["Bendamustine Hydrochloride Bendamustine Hydrochloride MONOTHIOGLYCEROL BENDAMUSTINE HYDROCHLORIDE Bendamustine POLYETHYLENE GLYCOL, UNSPECIFIED SODIUM HYDROXIDE ALCOHOL"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 100 mg/4 mL (25 mg/mL) as a clear and colorless to yellow solution in a multiple-dose vial. Injection: 100 mg/4mL (25 mg/mL) in a multiple-dose vial. ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Lactation: Advise not to breastfeed. ( 8.2 ) Infertility: May impair fertility. ( 8.3 ) Renal Impairment: Do not use in patients with creatinine clearance <30 mL/min. ( 8.6 ) Hepatic Impairment: Do not use in patients with total bilirubin 1.5-3 x ULN and AST or ALT 2.5-10 x ULN, or total bilirubin >3 x ULN. ( 8.7 ) 8.1 Pregnancy Risk Summary In animal reproduction studies, intraperitoneal administration of bendamustine to pregnant mice and rats during organogenesis at doses 0.6 to 1.8 times the maximum recommended human dose (MRHD) resulted in embryo-fetal and/or infant mortality, structural abnormalities, and alterations to growth (see Data). There are no available data on bendamustine hydrochloride use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Advise pregnant women of the potential risk to a fetus. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. Data Animal Data Bendamustine hydrochloride was intraperitoneally administered once to mice from 210 mg/m 2 (approximately 1.8 times the MRHD) during organogenesis and caused an increase in resorptions, skeletal and visceral malformations (exencephaly, cleft palates, accessory rib, and spinal deformities) and decreased fetal body weights. This dose did not appear to be maternally toxic and lower doses were not evaluated. Repeat intraperitoneal administration of bendamustine hydrochloride in mice on gestation days 7 to 11 resulted in an increase in resorptions from 75 mg/m 2 (approximately 0.6 times the MRHD) and an increase in abnormalities from 112.5 mg/m 2 (approximately 0.9 times the MRHD), similar to those seen after a single intraperitoneal administration. Bendamustine hydrochloride was intraperitoneally administered once to rats from 120 mg/m 2 (approximately the MRHD) on gestation days 4, 7, 9, 11, or 13 and caused embryo and fetal lethality as indicated by increased resorptions and a decrease in live fetuses. A significant increase in external (effect on tail, head, and herniation of external organs [exomphalos]) and internal (hydronephrosis and hydrocephalus) malformations were seen in dosed rats. 8.2 Lactation Risk Summary There are no data on the presence of bendamustine hydrochloride or its metabolites in either human or animal milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with bendamustine hydrochloride injection, and for 1 week after the last dose. 8.3 Females and Males of Reproductive Potential Bendamustine hydrochloride injection can cause embryo-fetal harm when administered to a pregnant woman [see Use in Specific Populations ( 8.1 )]. Pregnancy Testing Pregnancy testing is recommended for females of reproductive potential prior to initiation of treatment with bendamustine hydrochloride injection. Contraception Females Advise female patients of reproductive potential to use effective contraception during treatment with bendamustine hydrochloride injection and for 6 months after the last dose. Males Based on genotoxicity findings, advise males with female partners of reproductive potential to use effective contraception during treatment with bendamustine hydrochloride injection and for 3 months after the last dose [see Nonclinical Toxicology ( 13.1 )]. Infertility Based on findings from clinical studies, bendamustine hydrochloride injection may impair male fertility. Impaired spermatogenesis, azoospermia, and total germinal aplasia have been reported in male patients treated with alkylating agents, especially in combination with other drugs. In some instances, spermatogenesis may return in patients in remission, but this may occur only several years after intensive chemotherapy has been discontinued. Advise patients of the potential risk to their reproductive capacities. Based on findings from animal studies, bendamustine hydrochloride injection may impair male fertility due to an increase in morphologically abnormal spermatozoa. The long-term effects of bendamustine hydrochloride injection on male fertility, including the reversibility of adverse effects, have not been studied [see Nonclinical Toxicology ( 13.1 )]. 8.4 Pediatric Use Safety and effectiveness in pediatric patients have not been established. Safety, pharmacokinetics and efficacy were assessed in a single open-label trial (NCT01088984) in patients aged 1 to 19 years with relapsed or refractory acute leukemia, including 27 patients with acute lymphocytic leukemia (ALL) and 16 patients with acute myeloid leukemia (AML). Bendamustine hydrochloride was administered as an intravenous infusion over 60 minutes on Days 1 and 2 of each 21-day cycle. There was no treatment response (CR+ CRp) in any patient. The safety profile in these patients was consistent with that seen in adults, and no new safety signals were identified. The pharmacokinetics of bendamustine in 43 patients, aged 1 to 19 years (median age of 10 years) were within range of values previously observed in adults given the same dose based on body surface area. 8.5 Geriatric Use No overall differences in safety were observed between patients ≥65 years of age and younger patients. No overall differences in efficacy in patients with non-Hodgkin Lymphoma were observed between geriatric patients and younger patients. 8.6 Renal Impairment Do not use bendamustine hydrochloride injection in patients with creatinine clearance (CLcr) < 30 mL/min. [see Clinical Pharmacology ( 12.3 )] 8.7 Hepatic Impairment Do not use bendamustine hydrochloride injection in patients with AST or ALT 2.5 to 10 × upper limit of normal (ULN) and total bilirubin 1.5 to 3 × ULN, or total bilirubin > 3 × ULN [see Clinical Pharmacology (12.3 )]"],"information_for_patients_table":["<table frame=\"void\" rules=\"none\"><tbody><tr><td><content styleCode=\"bold\">Manufactured by:</content><content styleCode=\"bold\"/></td><td><content styleCode=\"bold\">Manufactured for:</content><content styleCode=\"bold\"/></td></tr><tr><td> MSN Laboratories Private Limited, India </td><td> Apotex Corp. </td></tr><tr><td> ML No. 5/MN/TS/2014/F/G </td><td> Weston, Florida  USA 33326 </td></tr></tbody></table>"],"dosage_and_administration_table":["<table frame=\"border\" rules=\"all\"><tbody><tr><th>Body Surface Area (m<sup>2</sup>)</th><th colspan=\"3\">Volume of Bendamustine Hydrochloride Injection to withdraw  (mL)</th></tr><tr><td align=\"center\"><content styleCode=\"bold\"/></td><td align=\"center\"><content styleCode=\"bold\">120 mg/m<sup>2</sup></content></td><td align=\"center\"><content styleCode=\"bold\">90 mg/m<sup>2</sup></content></td><td align=\"center\"><content styleCode=\"bold\">60 mg/m<sup>2</sup></content></td></tr><tr><td align=\"center\">1</td><td align=\"center\">4.8</td><td align=\"center\">3.6</td><td align=\"center\">2.4</td></tr><tr align=\"center\"><td>1.1</td><td>5.3</td><td>4</td><td>2.6</td></tr><tr align=\"center\"><td>1.2</td><td>5.8</td><td>4.3</td><td>2.9</td></tr><tr align=\"center\"><td>1.3</td><td>6.2</td><td>4.7</td><td>3.1</td></tr><tr align=\"center\"><td>1.4</td><td>6.7</td><td>5</td><td>3.4</td></tr><tr align=\"center\"><td>1.5</td><td>7.2</td><td>5.4</td><td>3.6</td></tr><tr align=\"center\"><td>1.6</td><td>7.7</td><td>5.8</td><td>3.8</td></tr><tr align=\"center\"><td>1.7</td><td>8.2</td><td>6.1</td><td>4.1</td></tr><tr align=\"center\"><td>1.8</td><td>8.6</td><td>6.5</td><td>4.3</td></tr><tr align=\"center\"><td>1.9</td><td>9.1</td><td>6.8</td><td>4.6</td></tr><tr align=\"center\"><td>2</td><td>9.6</td><td>7.2</td><td>4.8</td></tr><tr align=\"center\"><td>2.1</td><td>10.1</td><td>7.6</td><td>5</td></tr><tr align=\"center\"><td>2.2</td><td>10.6</td><td>7.9</td><td>5.3</td></tr><tr align=\"center\"><td>2.3</td><td>11</td><td>8.3</td><td>5.5</td></tr><tr align=\"center\"><td>2.4</td><td>11.5</td><td>8.6</td><td>5.8</td></tr><tr align=\"center\"><td>2.5</td><td>12</td><td>9</td><td>6</td></tr><tr align=\"center\"><td>2.6</td><td>12.5</td><td>9.4</td><td>6.2</td></tr><tr align=\"center\"><td>2.7</td><td>13</td><td>9.7</td><td>6.5</td></tr><tr align=\"center\"><td>2.8</td><td>13.4</td><td>10.1</td><td>6.7</td></tr><tr align=\"center\"><td>2.9</td><td>13.9</td><td>10.4</td><td>7</td></tr><tr align=\"center\"><td>3</td><td>14.4</td><td>10.8</td><td>7.2</td></tr></tbody></table>"],"package_label_principal_display_panel":["Bendamustine Hydrochloride Injection, 100 mg/4 mL (25 mg/mL) ctn-label-100mg"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Bendamustine was carcinogenic in mice. After intraperitoneal injections at 37.5 mg/m 2 /day (the lowest dose tested, approximately 0.3 times the maximum recommended human dose [MRHD]) and 75 mg/m 2 /day (approximately 0.6 times the MRHD) for 4 days, peritoneal sarcomas in female AB/jena mice were produced. Oral administration at 187.5 mg/m 2 /day (the only dose tested, approximately 1.6 times the MRHD) for 4 days induced mammary carcinomas and pulmonary adenomas. Bendamustine is a mutagen and clastogen. In a reverse bacterial mutation assay (Ames assay), bendamustine was shown to increase revertant frequency in the absence and presence of metabolic activation. Bendamustine was clastogenic in human lymphocytes in vitro, and in rat bone marrow cells in vivo (increase in micronucleated polychromatic erythrocytes) from 37.5 mg/m 2 (the lowest dose tested, approximately 0.3 times the MRHD). Bendamustine induced morphologic abnormalities in spermatozoa in mice. Following tail vein injection of bendamustine at 120 mg/m 2 or a saline control on days 1 and 2 for a total of 3 weeks, the number of spermatozoa with morphologic abnormalities was 16% higher in the bendamustine-treated group as compared to the saline control group."]},"tags":[{"label":"Alkylating Drug","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Histone deacetylase 6","category":"target"},{"label":"HDAC6","category":"gene"},{"label":"HDAC2","category":"gene"},{"label":"HDAC4","category":"gene"},{"label":"L01AA09","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Chronic lymphoid leukemia, disease","category":"indication"},{"label":"Diffuse large B-cell lymphoma refractory","category":"indication"},{"label":"Follicular non-Hodgkin's lymphoma","category":"indication"},{"label":"Indolent B-Cell Lymphoma","category":"indication"},{"label":"Treatment prior to tumor-specific T-cell infusion therapy","category":"indication"},{"label":"Baxter Hlthcare Corp","category":"company"},{"label":"Approved 2000s","category":"decade"},{"label":"Alkylating Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Alkylating","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"OFF LABEL USE","source":"FDA FAERS","actionTaken":"3006 reports"},{"date":"","signal":"DISEASE PROGRESSION","source":"FDA FAERS","actionTaken":"2717 reports"},{"date":"","signal":"PYREXIA","source":"FDA FAERS","actionTaken":"1865 reports"},{"date":"","signal":"NEUTROPENIA","source":"FDA FAERS","actionTaken":"1621 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"1341 reports"},{"date":"","signal":"FEBRILE NEUTROPENIA","source":"FDA FAERS","actionTaken":"1294 reports"},{"date":"","signal":"PNEUMONIA","source":"FDA FAERS","actionTaken":"1263 reports"},{"date":"","signal":"THROMBOCYTOPENIA","source":"FDA FAERS","actionTaken":"1262 reports"},{"date":"","signal":"COVID-19","source":"FDA FAERS","actionTaken":"1122 reports"},{"date":"","signal":"ANAEMIA","source":"FDA FAERS","actionTaken":"1115 reports"}],"drugInteractions":[{"url":"/drug/omeprazole","drug":"omeprazole","action":"Monitor closely","effect":"May interact with Omeprazole","source":"DrugCentral","drugSlug":"omeprazole"}],"commonSideEffects":[{"effect":"Pyrexia","drugRate":"24%","severity":"serious","_validated":true},{"effect":"Nausea","drugRate":"≥20%","severity":"serious","_validated":true},{"effect":"Vomiting","drugRate":"16%","severity":"serious","_validated":true},{"effect":"Fatigue","drugRate":"9%","severity":"common","_validated":true},{"effect":"Asthenia","drugRate":"8%","severity":"common","_validated":true},{"effect":"Diarrhea","drugRate":"9%","severity":"common","_validated":true},{"effect":"Weight decreased","drugRate":"7%","severity":"common","_validated":true},{"effect":"Hyperuricemia","drugRate":"7%","severity":"common","_validated":true},{"effect":"Cough","drugRate":"6%","severity":"common","_validated":true},{"effect":"Rash","drugRate":"8%","severity":"common","_validated":true},{"effect":"Hypersensitivity","drugRate":"5%","severity":"common","_validated":true},{"effect":"Nasopharyngitis","drugRate":"7%","severity":"common","_validated":true},{"effect":"Infection","drugRate":"6%","severity":"common","_validated":true},{"effect":"Herpes simplex","drugRate":"3%","severity":"mild","_validated":true},{"effect":"Pruritus","drugRate":"5%","severity":"mild","_validated":true},{"effect":"Chills","drugRate":"6%","severity":"mild","_validated":true},{"effect":"Anorexia","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Constipation","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Headache","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Dyspnea","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Stomatitis","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Leukopenia","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Lymphopenia","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Neutropenia","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Thrombocytopenia","drugRate":"≥5%","severity":"mild","_validated":true},{"effect":"Anemia","drugRate":"≥5%","severity":"mild","_validated":true}],"contraindications":["Acute infectious disease","Acute nephropathy","Anemia","Bone marrow depression","Breastfeeding (mother)","Chemotherapy-Induced Hyperuricemia","Disease of liver","Fluid volume disorder","Hepatic failure","Hyperkalemia","Kidney disease","Neutropenic disorder","Pregnancy, function","Smokes tobacco daily","Thrombocytopenic disorder"],"specialPopulations":{"Lactation":"There are no data on the presence of bendamustine hydrochloride or its metabolites in either human or animal milk, the effects on the breastfed child, or the effects on milk production. Because of the potential for serious adverse reactions in the breastfed child, advise patients that breastfeeding is not recommended during treatment with bendamustine hydrochloride, and for week after the last dose.","Pregnancy":"In animal reproduction studies, intraperitoneal administration of bendamustine to pregnant mice and rats during organogenesis at doses 0.6 to 1.8 times the maximum recommended human dose (MRHD) resulted in embryo-fetal and/or infant mortality, structural abnormalities, and alterations to growth. There are no available data on bendamustine hydrochloride use in pregnant women to evaluate for drug-associated risk of major birth defects, miscarriage or adverse maternal or fetal outcomes. Advise pregnant women of the potential risk to fetus.","Geriatric use":"No overall differences in safety were observed between patients >=65 years of age and younger patients. Efficacy was lower in patients 65 and over with CLL receiving bendamustine hydrochloride based upon an overall response rate of 47% for patients 65 and over and 70% for younger patients. Progression free survival was also longer in younger patients with CLL receiving bendamustine hydrochloride (19 months vs. 12 months). No overall differences in efficacy in patients with non","Paediatric use":"Safety and effectiveness in pediatric patients have not been established. Safety, pharmacokinetics and efficacy were assessed in single open-label trial (NCT01088984) in patients aged to 19 years with relapsed or refractory acute leukemia, including 27 patients with acute lymphocytic leukemia (ALL) and 16 patients with acute myeloid leukemia (AML). Bendamustine hydrochloride was administered as an intravenous infusion over 60 minutes on Days and of each 21-day cycle. There was ","Renal impairment":"Do not use in patients with creatinine clearance 30 mL/min","Hepatic impairment":"Do not use in patients with total bilirubin 1.5-3 ULN and AST or ALT 2.5-10 ULN, or total bilirubin 3 ULN"}},"trials":[],"aliases":[],"company":"Baxter","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=BENDAMUSTINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:51:25.123973+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:51:32.577636+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:51:23.751837+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BENDAMUSTINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:51:33.395879+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:51:22.513379+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:51:22.513413+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:51:34.894810+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL487253/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:51:33.860518+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA215033","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:51:22.513419+00:00"}},"allNames":"treanda","offLabel":[],"synonyms":["bendamustine","bendamustine hydrochloride","treanda","bendamustine HCl"],"timeline":[{"date":"2008-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from CEPHALON to Baxter Hlthcare Corp"},{"date":"2008-03-20","type":"positive","source":"DrugCentral","milestone":"FDA approval (Cephalon)"},{"date":"2010-09-27","type":"positive","source":"DrugCentral","milestone":"PMDA approval (SymBio Pharmaceuticals Limited)"},{"date":"2015-12-07","type":"positive","source":"FDA Orange Book","milestone":"Bendeka approved — 100MG/4ML (25MG/ML)"},{"date":"2018-05-15","type":"positive","source":"FDA Orange Book","milestone":"Belrapzo approved — 100MG/4ML (25MG/ML)"},{"date":"2022-12-07","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Apotex)"},{"date":"2023-04-28","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 4 manufacturers approved"},{"date":"2025-07-03","type":"positive","source":"FDA Orange Book","milestone":"New formulation approved (Dr Reddys)"}],"aiSummary":"Treanda (Bendamustine) is a small molecule alkylating drug that targets histone deacetylase 6. It was originally developed by Cephalon and is now owned by Baxter Healthcare Corp. Treanda is FDA-approved for the treatment of various types of lymphoma, including chronic lymphoid leukemia, diffuse large B-cell lymphoma, follicular non-Hodgkin's lymphoma, and indolent B-cell lymphoma. The drug is off-patent and has multiple generic manufacturers. Key safety considerations include its short half-life of 0.41 hours.","brandName":"Treanda","ecosystem":[{"indication":"Chronic lymphoid leukemia, disease","otherDrugs":[{"name":"chlorambucil","slug":"chlorambucil","company":"Aspen Global Inc"},{"name":"cyclophosphamide","slug":"cyclophosphamide","company":"Baxter Hlthcare"},{"name":"duvelisib","slug":"duvelisib","company":"Verastem Inc"},{"name":"fludarabine phosphate","slug":"fludarabine-phosphate","company":""}],"globalPrevalence":null},{"indication":"Diffuse large B-cell lymphoma refractory","otherDrugs":[{"name":"polatuzumab vedotin","slug":"polatuzumab-vedotin","company":"Genentech"},{"name":"tafasitamab","slug":"tafasitamab","company":"Morphosys Us Inc"}],"globalPrevalence":null},{"indication":"Follicular non-Hodgkin's lymphoma","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"bleomycin","slug":"bleomycin","company":"Bristol Myers Squibb"},{"name":"chlorambucil","slug":"chlorambucil","company":"Aspen Global Inc"},{"name":"cortisone acetate","slug":"cortisone-acetate","company":""}],"globalPrevalence":123507000},{"indication":"Indolent B-Cell Lymphoma","otherDrugs":[],"globalPrevalence":null},{"indication":"Treatment prior to tumor-specific T-cell infusion therapy","otherDrugs":[{"name":"cyclophosphamide","slug":"cyclophosphamide","company":"Baxter Hlthcare"},{"name":"etoposide","slug":"etoposide","company":""}],"globalPrevalence":null}],"mechanism":{"target":"Histone deacetylase 6","novelty":"Follow-on","targets":[{"gene":"HDAC6","source":"DrugCentral","target":"Histone deacetylase 6","protein":"Histone deacetylase 6"},{"gene":"HDAC2","source":"DrugCentral","target":"Histone deacetylase 2","protein":"Histone deacetylase 2"},{"gene":"HDAC4","source":"DrugCentral","target":"Histone deacetylase 4","protein":"Histone deacetylase 4"},{"gene":"HDAC5","source":"DrugCentral","target":"Histone deacetylase 5","protein":"Histone deacetylase 5"},{"gene":"HDAC1","source":"DrugCentral","target":"Histone deacetylase 1","protein":"Histone deacetylase 1"},{"gene":"HDAC3","source":"DrugCentral","target":"Histone deacetylase 3","protein":"Histone deacetylase 3"},{"gene":"HDAC10","source":"DrugCentral","target":"Histone deacetylase 10","protein":"Histone deacetylase 10"},{"gene":"HDAC8","source":"DrugCentral","target":"Histone deacetylase 8","protein":"Histone deacetylase 8"}],"moaClass":"Alkylating Activity","modality":"Small Molecule","drugClass":"Alkylating Drug","explanation":"Bendamustine is bifunctional mechlorethamine derivative containing purine-like benzimidazole ring. Mechlorethamine and its derivatives form electrophilic alkyl groups. These groups form covalent bonds with electron-rich nucleophilic moieties, resulting in interstrand DNA crosslinks. The bifunctional covalent linkage can lead to cell death via several pathways. Bendamustine is active against both quiescent and dividing cells. The exact mechanism of action of bendamustine remains unknown.","oneSentence":"Treanda works by attaching an alkyl group to the DNA of cancer cells, interfering with their ability to replicate and grow.","technicalDetail":"Bendamustine exerts its cytotoxic effects through the formation of DNA cross-links and DNA strand breaks, leading to cell cycle arrest and apoptosis in rapidly dividing cancer cells.","_target_confidence":0.5},"commercial":{"launchDate":"2008","_launchSource":"DrugCentral (FDA 2008-03-20, CEPHALON)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/302","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=BENDAMUSTINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=BENDAMUSTINE","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T08:58:19.077851","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:51:39.991490+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cyclophosphamide","drugSlug":"cyclophosphamide","fdaApproval":"1959-11-16","patentExpiry":"Jun 26, 2035","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"chlorambucil","drugSlug":"chlorambucil","fdaApproval":"1957-03-18","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"melphalan","drugSlug":"melphalan","fdaApproval":"1964-01-17","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"mechlorethamine","drugSlug":"mechlorethamine","fdaApproval":"1949-03-15","patentExpiry":"Mar 7, 2026","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"ifosfamide","drugSlug":"ifosfamide","fdaApproval":"1988-12-30","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"melphalan flufenamide","drugSlug":"melphalan-flufenamide","fdaApproval":"2021-02-26","relationship":"same-class"}],"genericName":"bendamustine","indications":{"approved":[{"name":"Chronic lymphoid leukemia, disease","source":"DrugCentral","snomedId":92814006,"regulator":"FDA"},{"name":"Diffuse large B-cell lymphoma refractory","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Follicular non-Hodgkin's lymphoma","source":"DrugCentral","snomedId":308121000,"regulator":"FDA","usPrevalence":null,"globalPrevalence":123507000,"prevalenceMethod":"curated","prevalenceSource":"J Insur Med, 2023 (PMID:37725503)"},{"name":"Indolent B-Cell Lymphoma","source":"DrugCentral","snomedId":"","regulator":"FDA"},{"name":"Treatment prior to tumor-specific T-cell infusion therapy","source":"DrugCentral","snomedId":"","regulator":"FDA"}],"offLabel":[{"name":"Mantle cell lymphoma","source":"DrugCentral","drugName":"BENDAMUSTINE","evidenceCount":322,"evidenceLevel":"strong"}],"pipeline":[]},"currentOwner":"Baxter Hlthcare Corp","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"cyclophosphamide","brandName":"cyclophosphamide","genericName":"cyclophosphamide","approvalYear":"1959","relationship":"same-class"},{"drugId":"chlorambucil","brandName":"chlorambucil","genericName":"chlorambucil","approvalYear":"1957","relationship":"same-class"},{"drugId":"melphalan","brandName":"melphalan","genericName":"melphalan","approvalYear":"1964","relationship":"same-class"},{"drugId":"mechlorethamine","brandName":"mechlorethamine","genericName":"mechlorethamine","approvalYear":"1949","relationship":"same-class"},{"drugId":"ifosfamide","brandName":"ifosfamide","genericName":"ifosfamide","approvalYear":"1988","relationship":"same-class"},{"drugId":"melphalan-flufenamide","brandName":"melphalan flufenamide","genericName":"melphalan flufenamide","approvalYear":"2021","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT05139017","phase":"PHASE2,PHASE3","title":"A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-14","conditions":["DLBCL","Diffuse Large B-Cell Lymphoma"],"enrollment":290,"completionDate":"2027-09-24"},{"nctId":"NCT01886872","phase":"PHASE3","title":"Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-01-15","conditions":["Stage I Chronic Lymphocytic Leukemia","Stage II Chronic Lymphocytic Leukemia","Stage III Chronic Lymphocytic Leukemia","Stage IV Chronic Lymphocytic Leukemia"],"enrollment":547,"completionDate":"2026-06-07"},{"nctId":"NCT03269669","phase":"PHASE2","title":"Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2018-01-23","conditions":["Grade 1 Follicular Lymphoma","Grade 2 Follicular Lymphoma","Grade 3a Follicular Lymphoma","Recurrent Follicular Lymphoma","Refractory Follicular Lymphoma"],"enrollment":73,"completionDate":"2027-01-21"},{"nctId":"NCT07139873","phase":"PHASE3","title":"A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)","status":"RECRUITING","sponsor":"Dizal (Jiangsu) Pharmaceutical Co., Ltd.","startDate":"2025-09-08","conditions":["Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma"],"enrollment":250,"completionDate":"2029-12"},{"nctId":"NCT07492407","phase":"","title":"CD20 Monoclonal Antibody-Based First-Line Therapy in Treatment-Naive Marginal Zone B-Cell Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Henan Cancer Hospital","startDate":"2026-04","conditions":["MZL"],"enrollment":131,"completionDate":"2028-02"},{"nctId":"NCT05888493","phase":"PHASE3","title":"A Phase III Trial Comparing Tisagenlecleucel to Standard of Care (SoC) in Adult Participants With r/r Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2023-10-02","conditions":["Follicular Lymphoma (FL)"],"enrollment":109,"completionDate":"2031-02-20"},{"nctId":"NCT04115631","phase":"PHASE2","title":"A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2019-12-13","conditions":["Liver Lymphoma","Mantle Cell Lymphoma"],"enrollment":360,"completionDate":"2026-12-31"},{"nctId":"NCT01479842","phase":"PHASE1","title":"Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin's Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kami Maddocks, MD","startDate":"2014-03-26","conditions":["Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue","Nodal Marginal Zone B-cell Lymphoma","Recurrent Adult Diffuse Large Cell Lymphoma","Recurrent Grade 1 Follicular Lymphoma","Recurrent Grade 2 Follicular Lymphoma","Recurrent Grade 3 Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Splenic Marginal Zone Lymphoma","Waldenstrom Macroglobulinemia"],"enrollment":48,"completionDate":"2026-09-01"},{"nctId":"NCT03570892","phase":"PHASE3","title":"Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2019-05-07","conditions":["Non-Hodgkin Lymphoma"],"enrollment":331,"completionDate":"2026-02-03"},{"nctId":"NCT04629729","phase":"PHASE1","title":"FT819 in Subjects With B-cell Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fate Therapeutics","startDate":"2021-07-12","conditions":["Lymphoma, B-Cell","Chronic Lymphocytic Leukemia","Precursor B-Cell Acute Lymphoblastic Leukemia"],"enrollment":54,"completionDate":"2039-09-30"},{"nctId":"NCT07477639","phase":"PHASE1,PHASE2","title":"Treatment of Participants With Primary or Secondary Progressive Multiple Sclerosis","status":"RECRUITING","sponsor":"Tr1X, Inc.","startDate":"2026-03","conditions":["Primary Progressive Multiple Sclerosis","Secondary Progressive Multiple Sclerosis (SPMS)","Multiple Sclerosis","Multiple Sclerosis (MS) Primary Progressive","Multiple Sclerosis (MS) Secondary Progressive"],"enrollment":39,"completionDate":"2029-01"},{"nctId":"NCT06846671","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-04-10","conditions":["CLL","Chronic Lymphocytic Leukemia"],"enrollment":250,"completionDate":"2030-02-14"},{"nctId":"NCT06549595","phase":"PHASE3","title":"A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2024-08-07","conditions":["Untreated Follicular Lymphoma"],"enrollment":1018,"completionDate":"2031-11-26"},{"nctId":"NCT06313996","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma","status":"WITHDRAWN","sponsor":"Juno Therapeutics, Inc., a Bristol-Myers Squibb Company","startDate":"2024-03-29","conditions":["Relapsed or Refractory Follicular Lymphoma"],"enrollment":0,"completionDate":"2031-10-16"},{"nctId":"NCT06483048","phase":"PHASE1","title":"MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-09-20","conditions":["Platinum-Resistant Fallopian Tube Carcinoma","Platinum-Resistant Ovarian Carcinoma","Platinum-Resistant Primary Peritoneal Carcinoma","Recurrent Fallopian Tube Carcinoma","Recurrent Fallopian Tube Carcinosarcoma","Recurrent Female Reproductive System Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Ovarian Carcinosarcoma","Recurrent Platinum-Resistant Fallopian Tube Carcinoma","Recurrent Platinum-Resistant Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Recurrent Primary Peritoneal Carcinosarcoma","Refractory Fallopian Tube Carcinoma","Refractory Female Reproductive System Carcinoma","Refractory Ovarian Carcinoma","Refractory Primary Peritoneal Carcinoma"],"enrollment":12,"completionDate":"2028-09-30"},{"nctId":"NCT05624554","phase":"PHASE3","title":"A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-03-16","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"enrollment":300,"completionDate":"2031-03-17"},{"nctId":"NCT06091254","phase":"PHASE3","title":"A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2023-12-12","conditions":["Follicular Lymphoma (FL)"],"enrollment":822,"completionDate":"2029-11-03"},{"nctId":"NCT06308978","phase":"PHASE1","title":"A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease","status":"RECRUITING","sponsor":"Fate Therapeutics","startDate":"2024-03-28","conditions":["Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV)","Idiopathic Inflammatory Myositis (IIM)","Systemic Sclerosis (SSc)","Systemic Lupus Erythematosus (SLE)"],"enrollment":244,"completionDate":"2042-09-30"},{"nctId":"NCT03336333","phase":"PHASE3","title":"A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2017-10-31","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"enrollment":590,"completionDate":"2027-10-31"},{"nctId":"NCT07225985","phase":"PHASE1,PHASE2","title":"Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2026-05-01","conditions":["Recurrent T-Cell Non-Hodgkin Lymphoma","Refractory T-Cell Non-Hodgkin Lymphoma"],"enrollment":50,"completionDate":"2030-11-15"},{"nctId":"NCT07450508","phase":"PHASE3","title":"Study of Bendamustine, Gemcitabine and Vinorelbine Regimen in Relapsed/Refractory Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Cairo University","startDate":"2024-04-30","conditions":["Classical Hodgkin Lymphoma Relapsed"],"enrollment":88,"completionDate":"2026-02-01"},{"nctId":"NCT04285567","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without DEL (17P) or TP53 Mutation","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2020-05-28","conditions":["Chronic Lymphocytic Leukemia (CLL)"],"enrollment":166,"completionDate":"2025-03-19"},{"nctId":"NCT04663347","phase":"PHASE1,PHASE2","title":"Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Genmab","startDate":"2020-11-03","conditions":["Diffuse Large B-Cell Lymphoma","Follicular Lymphoma"],"enrollment":543,"completionDate":"2027-09-30"},{"nctId":"NCT06191744","phase":"PHASE3","title":"Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma","status":"RECRUITING","sponsor":"Genmab","startDate":"2024-02-05","conditions":["Follicular Lymphoma (FL)"],"enrollment":1095,"completionDate":"2037-11"},{"nctId":"NCT06084936","phase":"PHASE3","title":"A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2023-10-22","conditions":["Lymphoma"],"enrollment":182,"completionDate":"2028-03-31"},{"nctId":"NCT06504940","phase":"PHASE2","title":"Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2024-06-28","conditions":["Marginal Zone Lymphoma"],"enrollment":69,"completionDate":"2029-07-08"},{"nctId":"NCT06138132","phase":"PHASE1","title":"A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis","status":"RECRUITING","sponsor":"Stanford University","startDate":"2024-04-10","conditions":["Multiple Sclerosis","Multiple Sclerosis, Primary Progressive","Multiple Sclerosis, Secondary Progressive"],"enrollment":12,"completionDate":"2027-06"},{"nctId":"NCT03609593","phase":"PHASE2","title":"Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Nicole Lamanna","startDate":"2018-11-12","conditions":["Chronic Lymphocytic Leukemia"],"enrollment":42,"completionDate":"2026-01-27"},{"nctId":"NCT03755804","phase":"PHASE2","title":"Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2018-12-12","conditions":["Hodgkin Lymphoma"],"enrollment":232,"completionDate":"2028-07-01"},{"nctId":"NCT06854003","phase":"PHASE2","title":"BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma","status":"RECRUITING","sponsor":"Christine Ryan","startDate":"2025-04-22","conditions":["Mantle Cell Lymphoma","Lymphoma"],"enrollment":60,"completionDate":"2039-11-01"},{"nctId":"NCT02972840","phase":"PHASE3","title":"A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-04-05","conditions":["Lymphoma, Mantle Cell"],"enrollment":635,"completionDate":"2027-02-15"},{"nctId":"NCT05551936","phase":"PHASE1,PHASE2","title":"A Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaishalee Kenkre","startDate":"2023-01-26","conditions":["Follicular Lymphoma"],"enrollment":42,"completionDate":"2027-05"},{"nctId":"NCT06191887","phase":"PHASE1","title":"B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-03-18","conditions":["B-Cell Non-Hodgkin Lymphoma","Recurrent Chronic Lymphocytic Leukemia","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Follicular Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Small Lymphocytic Lymphoma","Recurrent Transformed Chronic Lymphocytic Leukemia","Refractory Chronic Lymphocytic Leukemia","Refractory Diffuse Large B-Cell Lymphoma","Refractory Follicular Lymphoma","Refractory Mantle Cell Lymphoma","Refractory Marginal Zone Lymphoma","Refractory Small Lymphocytic Lymphoma","Refractory Transformed Chronic Lymphocytic Leukemia"],"enrollment":27,"completionDate":"2040-12-31"},{"nctId":"NCT06522737","phase":"PHASE3","title":"A Study of Duvelisib Versus Gemcitabine or Bendamustine in Participants With Relapsed/Refractory Nodal T Cell Lymphoma With T Follicular Helper (TFH) Phenotype","status":"RECRUITING","sponsor":"SecuraBio","startDate":"2025-05-19","conditions":["Lymphoma"],"enrollment":124,"completionDate":"2028-12"},{"nctId":"NCT04674813","phase":"PHASE1","title":"A Study of CC-95266 in Participants With Relapsed and/or Refractory Multiple Myeloma","status":"COMPLETED","sponsor":"Juno Therapeutics, a Subsidiary of Celgene","startDate":"2021-02-24","conditions":["Multiple Myeloma"],"enrollment":130,"completionDate":"2025-12-22"},{"nctId":"NCT02970318","phase":"PHASE3","title":"A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2017-02-02","conditions":["Chronic Lymphocytic Leukemia"],"enrollment":310,"completionDate":"2027-10-01"},{"nctId":"NCT04624906","phase":"PHASE2","title":"Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sunnybrook Health Sciences Centre","startDate":"2021-03-02","conditions":["Waldenstrom Macroglobulinemia"],"enrollment":63,"completionDate":"2030-03"},{"nctId":"NCT05300282","phase":"PHASE1,PHASE2","title":"Study of Atezolizumab Plus BEGEV Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2023-02-27","conditions":["Relapsed or Refractory Hodgkin's Lymphoma"],"enrollment":122,"completionDate":"2030-04-27"},{"nctId":"NCT05023980","phase":"PHASE3","title":"A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Loxo Oncology, Inc.","startDate":"2021-09-23","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"enrollment":309,"completionDate":"2027-10"},{"nctId":"NCT04223765","phase":"PHASE1","title":"Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2020-11-12","conditions":["Mantle Cell Lymphoma","Follicular Lymphoma","Splenic Marginal Zone Lymphoma","Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue","Nodal Marginal Zone Lymphoma","Indolent Non-hodgkin Lymphoma"],"enrollment":20,"completionDate":"2043-03-22"},{"nctId":"NCT02717624","phase":"PHASE1","title":"A Study of Acalabrutinib in Combination With Rituximab + (Bendamustine or Venetoclax) in Subjects With MCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"Acerta Pharma BV","startDate":"2016-04-20","conditions":["Mantle Cell Lymphoma (MCL)"],"enrollment":72,"completionDate":"2027-08-20"},{"nctId":"NCT05508867","phase":"PHASE2","title":"A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (MK-4280A-008)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-10-18","conditions":["Hodgkin Lymphoma"],"enrollment":203,"completionDate":"2026-01-08"},{"nctId":"NCT04022239","phase":"PHASE1,PHASE2","title":"Bendamustine With or Without Cyclophosphamide in Preventing GVHD in Patients Undergoing Stem Cell Transplant","status":"RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-03-13","conditions":["Hematopoietic and Lymphoid System Neoplasm"],"enrollment":25,"completionDate":"2027-07-31"},{"nctId":"NCT06425302","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of Golcadomide in Combination With Rituximab in Participants With Newly Diagnosed Advanced Stage Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Celgene","startDate":"2024-08-30","conditions":["Lymphoma, Follicular"],"enrollment":90,"completionDate":"2028-11-27"},{"nctId":"NCT06970743","phase":"PHASE3","title":"A Study of BGB-16673 Compared to Investigator's Choice in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Covalent Bruton Tyrosine Kinase (BTK) Inhibitors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2025-05-29","conditions":["Chronic Lymphocytic Leukemia","Small Lymphocytic Lymphoma"],"enrollment":150,"completionDate":"2029-11-30"},{"nctId":"NCT03602157","phase":"PHASE1","title":"Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-12-12","conditions":["Lymphoma","Immune System Diseases","Immunoproliferative Disorders","Lymphatic Diseases","Lymphoproliferative Disorders","Neoplasms","Cutaneous Lymphoma","Cutaneous Anaplastic Large Cell Lymphoma","Mycosis Fungoides","Sezary Syndrome","Lymphomatoid Papulosis","Cutaneous T Cell Lymphoma","Gray Zone Lymphoma"],"enrollment":43,"completionDate":"2039-11-04"},{"nctId":"NCT05249959","phase":"PHASE2","title":"Consolidation With Loncastuximab Tesirine After a Short Course of Immunochemotherapy in BTKi-treated (or Intolerant) Relapsed/Refractory Mantle Cell Lymphoma Patients.","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2022-03-21","conditions":["Relapsed Mantle Cell Lymphoma","Refractory Mantle Cell Lymphoma"],"enrollment":49,"completionDate":"2029-03"},{"nctId":"NCT05816850","phase":"","title":"Multilayer Biological Characterization of Advanced Follicular Lymphoma: a Translational Study From FIL_FOLL12 Trial","status":"RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2023-09-19","conditions":["Follicular Lymphoma"],"enrollment":654,"completionDate":"2027-06-01"},{"nctId":"NCT07166549","phase":"PHASE1","title":"Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2026-06","conditions":["B Cell Malignancies","B-cell Leukemia","B Cell Lymphoma","Bispecific Chimeric Antigen Receptor (CAR) T Cells","Relapsed or Refractory (r/r) B-cell Malignancies"],"enrollment":12,"completionDate":"2028-11"},{"nctId":"NCT06043713","phase":"PHASE1","title":"Autologous CD8+ and CD4+ Transgenic T Cells Expressing High Affinity KRASG12V Mutation-Specific T Cell Receptors (FH-A11KRASG12V-TCR) in Treating Patients With Metastatic Solid Tumor Cancers With KRAS G12V Mutations","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2023-12-15","conditions":["Metastatic Malignant Solid Neoplasm"],"enrollment":24,"completionDate":"2028-01-01"},{"nctId":"NCT06006117","phase":"PHASE3","title":"Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone Lymphoma","status":"RECRUITING","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2023-09-05","conditions":["Marginal Zone Lymphoma"],"enrollment":260,"completionDate":"2032-09"},{"nctId":"NCT07189065","phase":"PHASE2","title":"A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell Lymphoma","status":"RECRUITING","sponsor":"Guangzhou Lupeng Pharmaceutical Company LTD.","startDate":"2025-11-27","conditions":["Diffuse Large B-Cell Lymphoma (DLBCL)"],"enrollment":150,"completionDate":"2028-12-31"},{"nctId":"NCT05182073","phase":"PHASE1","title":"FT576 in Subjects With Multiple Myeloma","status":"COMPLETED","sponsor":"Fate Therapeutics","startDate":"2021-11-10","conditions":["Multiple Myeloma","Myeloma"],"enrollment":31,"completionDate":"2024-10-18"},{"nctId":"NCT06241456","phase":"PHASE1","title":"FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Fate Therapeutics","startDate":"2024-01-05","conditions":["Advanced Solid Tumor"],"enrollment":351,"completionDate":"2044-05-01"},{"nctId":"NCT03696784","phase":"PHASE1","title":"Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-03-12","conditions":["Lymphoma","Lymphoma, B-Cell","Immune System Diseases","Immunoproliferative Disorders","Lymphatic Diseases"],"enrollment":19,"completionDate":"2040-07-31"},{"nctId":"NCT03567876","phase":"PHASE2","title":"Rituximab, Bendamustine and Cytarabine Followed by Venetoclax in High Risk Elderly Patients With MCL","status":"COMPLETED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2018-09-03","conditions":["Lymphoma, Mantle-Cell"],"enrollment":141,"completionDate":"2025-10-15"},{"nctId":"NCT06911502","phase":"PHASE3","title":"A Study to Compare the Efficacy and Safety of Golcadomide in Combination With Rituximab (Golca + R) vs Investigator's Choice in Participants With Relapsed/Refractory Follicular Lymphoma Who Have Received at Least 1 Prior Line of Systemic Therapy (GOLSEEK-4)","status":"RECRUITING","sponsor":"Celgene","startDate":"2025-07-28","conditions":["Follicular Lymphoma"],"enrollment":400,"completionDate":"2030-07-31"},{"nctId":"NCT03352765","phase":"PHASE1","title":"A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-11-20","conditions":["Lymphoma"],"enrollment":28,"completionDate":"2026-11"},{"nctId":"NCT07259122","phase":"PHASE2","title":"A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Dose Bendamustine in the Treatment of Untreated Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-12-30","conditions":["Waldenström Macroglobulinemia (WM)"],"enrollment":43,"completionDate":"2032-06-30"},{"nctId":"NCT06561347","phase":"PHASE2","title":"Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM","status":"RECRUITING","sponsor":"Massachusetts General Hospital","startDate":"2024-12-20","conditions":["Waldenstrom Macroglobulinemia"],"enrollment":55,"completionDate":"2027-12-01"},{"nctId":"NCT01286272","phase":"PHASE2","title":"Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2011-04-28","conditions":["Ann Arbor Stage III Grade 1 Follicular Lymphoma","Ann Arbor Stage III Grade 2 Follicular Lymphoma","Ann Arbor Stage III Grade 3 Follicular Lymphoma","Ann Arbor Stage IV Grade 1 Follicular Lymphoma","Ann Arbor Stage IV Grade 2 Follicular Lymphoma","Ann Arbor Stage IV Grade 3 Follicular Lymphoma","Grade 3a Follicular Lymphoma"],"enrollment":135,"completionDate":"2025-09-02"},{"nctId":"NCT07145125","phase":"","title":"Real-life Efficacy and Toxicity of Brentuximab-Vedotin Associated With Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma (HL-R2-B2)","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2025-02-01","conditions":["Relapsed or Refractory Hodgkin Lymphoma"],"enrollment":222,"completionDate":"2025-09-30"},{"nctId":"NCT07238712","phase":"PHASE2","title":"Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor","status":"RECRUITING","sponsor":"St. Petersburg State Pavlov Medical University","startDate":"2025-05-10","conditions":["Acute Myeloid Leukemia (AML)","Chronic Myeloid Leukemia","Myelodysplastic Syndromes (MDS)","Myeloprolipherative Neoplsm","Atypical Chronic Myeloid Leukemia"],"enrollment":60,"completionDate":"2026-12-10"},{"nctId":"NCT02996773","phase":"PHASE1","title":"Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine","status":"COMPLETED","sponsor":"University of Arizona","startDate":"2016-11-29","conditions":["Acute Lymphoblastic Leukemia","Acute Myelogenous Leukemia","Myelodysplastic Syndromes","Chronic Myelogenous Leukemia","Lymphoma,Non-Hodgkin","Lymphoma, Hodgkin","Lymphoma, Follicular","Marginal Zone Lymphoma","Large Cell Lymphoma","Mantle-Cell Lymphoma","Gray Zone Lymphoma","Burkitt Lymphoma","High Risk Undifferentiated Acute Leukemia"],"enrollment":50,"completionDate":"2025-08-01"},{"nctId":"NCT06090864","phase":"PHASE1,PHASE2","title":"ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2024-04-25","conditions":["Hodgkin Lymphoma","Relapse","Refractory"],"enrollment":31,"completionDate":"2031-07-01"},{"nctId":"NCT03856216","phase":"PHASE2","title":"Inotuzumab Ozogamicin and Chemotherapy in Treating Patients With Leukemia or Lymphoma Undergoing Stem Cell Transplantation","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-10-28","conditions":["Acute Lymphoblastic Leukemia","B Acute Lymphoblastic Leukemia","Lymphocytic Neoplasm","Lymphoma"],"enrollment":15,"completionDate":"2025-10-13"},{"nctId":"NCT05371093","phase":"PHASE3","title":"Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kite, A Gilead Company","startDate":"2022-09-22","conditions":["Relapsed/Refractory Follicular Lymphoma"],"enrollment":231,"completionDate":"2030-10"},{"nctId":"NCT02315157","phase":"PHASE1","title":"Bendamustine Hydrochloride in Treating Patients With Previously Treated Multiple Myeloma","status":"WITHDRAWN","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2014-06","conditions":["Multiple Myeloma","Plasma Cell Leukemia"],"enrollment":0,"completionDate":"2018-11"},{"nctId":"NCT07208981","phase":"PHASE2","title":"Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-08-14","conditions":["Marginal Zone Lymphoma(MZL)"],"enrollment":169,"completionDate":"2031-06-01"},{"nctId":"NCT02153580","phase":"PHASE1","title":"Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2014-09-24","conditions":["B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma","B-Cell Prolymphocytic Leukemia","High Grade B-Cell Lymphoma, Not Otherwise Specified","Post-Transplant Lymphoproliferative Disorder","Recurrent Adult Burkitt Lymphoma","Recurrent Chronic Lymphocytic Leukemia","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Follicular Lymphoma","Recurrent Hairy Cell Leukemia","Recurrent Lymphoplasmacytic Lymphoma","Recurrent Mantle Cell Lymphoma","Recurrent Marginal Zone Lymphoma","Recurrent Small Lymphocytic Lymphoma"],"enrollment":37,"completionDate":"2026-09-02"},{"nctId":"NCT07206264","phase":"PHASE2","title":"Chemotherapy Combined With Targeted Therapy as First-line Treatment for Mantle Cell Lymphoma Based on MRD and PET-CT Assessment","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-10","conditions":["Mantle Cell Lymphoma"],"enrollment":45,"completionDate":"2028-12"},{"nctId":"NCT04607772","phase":"PHASE1,PHASE2","title":"Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)","status":"WITHDRAWN","sponsor":"Karyopharm Therapeutics Inc","startDate":"2020-11-18","conditions":["Relapsed or Refractory Diffuse Large B-Cell Lymphoma"],"enrollment":0,"completionDate":"2025-12"},{"nctId":"NCT04002297","phase":"PHASE3","title":"A Study to Investigate the Efficacy of Zanubrutinib Plus Rituximab Compared With Bendamustine Plus Rituximab in Adults With Previously Untreated Mantle Cell Lymphoma Who Are Ineligible for Stem Cell Transplantation","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2019-08-20","conditions":["Mantle Cell Lymphoma; Non-Hodgkin Lymphoma"],"enrollment":510,"completionDate":"2027-12"},{"nctId":"NCT01650701","phase":"PHASE3","title":"A Phase 3 Open Label Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Chemotherapy Followed by Rituximab in Subjects With Previously Untreated Follicular Lymphoma","status":"COMPLETED","sponsor":"The Lymphoma Academic Research Organisation","startDate":"2012-02","conditions":["Follicular Lymphoma"],"enrollment":1030,"completionDate":"2024-04-30"},{"nctId":"NCT04083495","phase":"PHASE2","title":"CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma","status":"RECRUITING","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2019-09-17","conditions":["Peripheral T Cell Lymphoma"],"enrollment":20,"completionDate":"2038-08"},{"nctId":"NCT07169565","phase":"PHASE1","title":"Ibrutinib Followed by BR (Bendamustine and Rituximab) as a Time-Limited Therapy for Waldenström Macroglobulinemia","status":"NOT_YET_RECRUITING","sponsor":"Institute of Hematology & Blood Diseases Hospital, China","startDate":"2025-09-01","conditions":["Waldenström Macroglobulinemia (WM)"],"enrollment":21,"completionDate":"2028-09-01"},{"nctId":"NCT05058404","phase":"PHASE3","title":"Shortened vs Standard Chemotherapy Combined With Immunotherapy for the Initial Treatment of Patients With High Tumor Burden Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2021-12-01","conditions":["Follicular Lymphoma"],"enrollment":605,"completionDate":"2030-07"},{"nctId":"NCT07059650","phase":"PHASE1,PHASE2","title":"DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)","status":"RECRUITING","sponsor":"Dizal Pharmaceuticals","startDate":"2025-08-19","conditions":["Diffuse Large B-Cell Lymphoma"],"enrollment":150,"completionDate":"2030-10"},{"nctId":"NCT05950334","phase":"PHASE1","title":"FT522 With Rituximab in Relapsed/Refractory B-Cell Lymphoma (FT522-101)","status":"COMPLETED","sponsor":"Fate Therapeutics","startDate":"2023-11-16","conditions":["Relapsed/Refractory B-Cell Lymphoma"],"enrollment":20,"completionDate":"2025-06-30"},{"nctId":"NCT03039114","phase":"PHASE1","title":"Study Evaluating Safety and Efficacy of INCB050465 Combined With Bendamustine and Obinutuzumab in Relapsed or Refractory Follicular Lymphoma (CITADEL-102)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-02-15","conditions":["Lymphoma"],"enrollment":26,"completionDate":"2021-03-30"},{"nctId":"NCT03424122","phase":"PHASE1","title":"INCB050465 in Combination With Rituximab, Bendamustine and Rituximab, or Ibrutinib in Participants With Previously Treated B-Cell Lymphoma (CITADEL-112)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2018-07-02","conditions":["B-cell Lymphoma"],"enrollment":50,"completionDate":"2022-06-27"},{"nctId":"NCT07126678","phase":"NA","title":"Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-07-15","conditions":["Follicular Lymphoma","Treatment Naive"],"enrollment":15,"completionDate":"2028-12-30"},{"nctId":"NCT03834688","phase":"PHASE2","title":"Phase II Study of Bendamustine and Rituximab Plus Venetoclax in Untreated Mantle Cell Lymphoma Over 60 Years of Age","status":"COMPLETED","sponsor":"PrECOG, LLC.","startDate":"2020-01-13","conditions":["Mantle Cell Lymphoma"],"enrollment":33,"completionDate":"2024-07-26"},{"nctId":"NCT04433182","phase":"PHASE2","title":"Copanlisib With Rituximab-Bendamustine in Patients With Relapsed-Refractory Diffuse Large B-cell Lymphoma","status":"TERMINATED","sponsor":"Fondazione Italiana Linfomi - ETS","startDate":"2020-08-18","conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":37,"completionDate":"2024-12-19"},{"nctId":"NCT03739619","phase":"PHASE1,PHASE2","title":"Gemcitabine, Bendamustine, and Nivolumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma","status":"COMPLETED","sponsor":"Emory University","startDate":"2018-11-26","conditions":["Recurrent Hodgkin Lymphoma","Refractory Hodgkin Lymphoma","Classical Hodgkin Lymphoma","Hodgkin Lymphoma"],"enrollment":3,"completionDate":"2025-04-30"},{"nctId":"NCT03872180","phase":"PHASE2","title":"Bendamustine, Obinutuzumab, and Venetoclax in Patients With Untreated Mantle Cell Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2019-04-11","conditions":["CCND1 Positive","Mantle Cell Lymphoma","t(11;14) Positive"],"enrollment":23,"completionDate":"2026-04-30"},{"nctId":"NCT02278796","phase":"PHASE2","title":"A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)","status":"COMPLETED","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2015-04","conditions":["Lymphoma, Large B-Cell, Diffuse","Lymphoma, Follicular","Lymphoma, Mantle-Cell"],"enrollment":108,"completionDate":"2020-11"},{"nctId":"NCT07072221","phase":"NA","title":"Bendamustine Combined With Chidamide and Lenalidomide for Relapsed and Refractory PTCL Patients","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Soochow University","startDate":"2024-11-01","conditions":["Peripheral T-cell Lymphoma"],"enrollment":40,"completionDate":"2029-11-01"},{"nctId":"NCT02763319","phase":"PHASE2,PHASE3","title":"A Trial to Evaluate the Efficacy and Safety of Tafasitamab With Bendamustine (BEN) Versus Rituximab (RTX) With BEN in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2016-11-28","conditions":["Diffuse Large B-cell Lymphoma"],"enrollment":453,"completionDate":"2024-06-21"},{"nctId":"NCT05451771","phase":"PHASE1,PHASE2","title":"Venetoclax-Dexamethasone in Relapsed and/or Refractory t(11;14) Amyloidosis","status":"RECRUITING","sponsor":"Rajshekhar Chakraborty, MD","startDate":"2022-10-26","conditions":["AL Amyloidosis"],"enrollment":53,"completionDate":"2026-09"},{"nctId":"NCT01776840","phase":"PHASE3","title":"A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2013-05-16","conditions":["Mantle Cell Lymphoma"],"enrollment":523,"completionDate":"2024-06-24"},{"nctId":"NCT04892277","phase":"PHASE1","title":"CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2022-10-03","conditions":["Recurrent B-Cell Non-Hodgkin Lymphoma","Recurrent Chronic Lymphocytic Leukemia","Recurrent Small Lymphocytic Lymphoma","Recurrent Transformed Chronic Lymphocytic Leukemia","Refractory B-Cell Non-Hodgkin Lymphoma","Refractory Chronic Lymphocytic Leukemia","Refractory Small Lymphocytic Lymphoma","Refractory Transformed Chronic Lymphocytic Leukemia"],"enrollment":25,"completionDate":"2040-03-27"},{"nctId":"NCT05025423","phase":"PHASE2","title":"Phase II Trial of Venetoclax and Rituximab as Initial Therapy in Older Patients With Mantle Cell Lymphoma","status":"TERMINATED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2022-06-21","conditions":["Mantle Cell Lymphoma"],"enrollment":7,"completionDate":"2025-05-14"},{"nctId":"NCT01059786","phase":"PHASE2","title":"Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2010-07-01","conditions":["Hairy Cell Leukemia"],"enrollment":69,"completionDate":"2027-12-31"},{"nctId":"NCT04673617","phase":"PHASE1,PHASE2","title":"AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Artiva Biotherapeutics, Inc.","startDate":"2021-03-29","conditions":["Non Hodgkin Lymphoma"],"enrollment":45,"completionDate":"2025-12-31"},{"nctId":"NCT02414022","phase":"","title":"Economic Analysis of Alliance A041202 CLL Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Canadian Cancer Trials Group","startDate":"2015-04-15","conditions":["Chronic Lymphocytic Leukemia"],"enrollment":55,"completionDate":"2026-04-09"},{"nctId":"NCT04515238","phase":"PHASE2","title":"Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL","status":"ACTIVE_NOT_RECRUITING","sponsor":"German CLL Study Group","startDate":"2020-10-01","conditions":["Chronic Lymphoid Leukemia"],"enrollment":42,"completionDate":"2026-12"},{"nctId":"NCT02401503","phase":"PHASE2","title":"Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG)","status":"COMPLETED","sponsor":"German CLL Study Group","startDate":"2015-05-06","conditions":["Chronic Lymphocytic Leucemia"],"enrollment":66,"completionDate":"2024-12-17"},{"nctId":"NCT04727151","phase":"PHASE1,PHASE2","title":"TAC T-cells for the Treatment of HER2-positive Solid Tumors","status":"TERMINATED","sponsor":"Triumvira Immunologics, Inc.","startDate":"2021-04-19","conditions":["HER2 Positive Gastric Cancer","Metastatic HER2 Positive Gastroesophageal Junction Cancer"],"enrollment":28,"completionDate":"2024-03-25"},{"nctId":"NCT07008053","phase":"PHASE2","title":"BR Combined With OR in Treatment-naïve Marginal Zone Lymphoma","status":"NOT_YET_RECRUITING","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2025-07","conditions":["Marginal Zone Lymphomas"],"enrollment":37,"completionDate":"2028-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION","route":"INTRAVENOUS","productName":"BELRAPZO"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"BENDAMUSTINE HYDROCHLORIDE"},{"form":"INJECTION","route":"INTRAVENOUS","productName":"VIVIMUSTA"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"BENDAMUSTINE HYDROCHLORIDE"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Bendamustine"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"Bendamustine Hydrochloride"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"bendamustine hydrochloride"},{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","productName":"TREANDA"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Bendamustine Hydrochloride"},{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Bendeka"},{"form":"INJECTION, SOLUTION, CONCENTRATE","route":"INTRAVENOUS","productName":"TREANDA"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000179513","MMSL":"132929","NDDF":"006925","UNII":"9266D9P3PQ","VUID":"4027339","CHEBI":"CHEBI:135515","VANDF":"4027339","INN_ID":"5228","RXNORM":"1114693","UMLSCUI":"C0525079","chemblId":"CHEMBL487253","ChEMBL_ID":"CHEMBL487253","KEGG_DRUG":"D07085","DRUGBANK_ID":"DB06769","PUBCHEM_CID":"65628","SNOMEDCT_US":"427812009","IUPHAR_LIGAND_ID":"7478","SECONDARY_CAS_RN":"3543-75-7","MESH_DESCRIPTOR_UI":"D000069461"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION","route":"INTRAVENOUS","company":"Cephalon, Inc.","brandName":"TREANDA","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","_offLabelChecked":true,"developmentCodes":[],"ownershipHistory":[{"period":"2008-","companyName":"Cephalon","relationship":"Original Developer"},{"period":"present","companyName":"Baxter Hlthcare Corp","relationship":"Current Owner"},{"period":"2010","companyName":"SymBio Pharmaceuticals Limited","relationship":"PMDA Licensee"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"0.41 hours","clearance":"4.49 mL/min/kg","fractionUnbound":"0.05%","volumeOfDistribution":"0.22 L/kg"},"publicationCount":2107,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01AA09","allCodes":["L01AA09"]},"biosimilarFilings":[],"originalDeveloper":"Cephalon","recentPublications":[],"companionDiagnostics":[],"genericManufacturers":8,"_genericFilersChecked":true,"genericManufacturerList":["Accord Hlthcare","Apotex","Breckenridge","Dr Reddys","Eugia Pharma","Meitheal","Nang Kuang Pharm Co","Pharmobedient"],"status":"approved","companyName":"Baxter Hlthcare Corp","companyId":"baxter","modality":"Small molecule","firstApprovalDate":"2008","enrichmentLevel":4,"visitCount":1,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2016-09-23T00:00:00.000Z","mah":"EAGLE PHARMS","brand_name_local":null,"application_number":"NDA208194"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-06-05T00:00:00.000Z","mah":"EUGIA PHARMA","brand_name_local":null,"application_number":"ANDA214739"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2023-06-05T00:00:00.000Z","mah":"MEITHEAL","brand_name_local":null,"application_number":"ANDA211001"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-02-08T00:00:00.000Z","mah":"AZURITY","brand_name_local":null,"application_number":"NDA212209"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2024-04-15T00:00:00.000Z","mah":"APOTEX","brand_name_local":null,"application_number":"NDA215033"},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":3,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:51:39.991490+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}